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A MARKET TEST FOR BAYH–DOLE PATENTS
Ian Ayres† & Lisa Larrimore Ouellette‡
The Bayh–Dole Act, which allows patenting of federally
funded research, has been praised for driving growth but also
criticized for creating unnecessary deadweight loss and contributing to a patent “anticommons.” Much of the controversy
stems from Bayh–Dole’s differing effects on different inventions. The dominant justification for Bayh–Dole patents is
commercialization theory: the idea that exclusive rights are
necessary to bring inventions to market. This theory is convincing for inventions like pharmaceuticals with high regulatory barriers and low imitation costs, but not when exclusivity
is unnecessary for commercialization, such as for Stanford’s
widely licensed patents on early recombinant DNA technology.
The problem is that for many government-funded inventions it
is difficult to determine whether exclusive patent grants are
necessary to incentivize commercialization.
To solve this difficulty, we propose a “market test” for
federally funded inventions at universities and other nonprofits. Before charging significant licensing fees for these inventions, these federal grant recipients would first be required to
find out whether firms would be willing to commercialize the
invention in exchange for a nonexclusive license with a nominal fee. If a company is willing to commit to developing the
invention under a nonexclusive license, then an exclusive license—or a nonexclusive license with high fees—would be
contrary to the public interest. More generally, using a formal
economic model, we show that deadweight loss can be reduced through an auction that forces bidders to reveal the
least amount of exclusivity needed to induce commercialization, that revenue cap bidding is more efficient than duration
bidding, and that defensive bidding by firms that consume as
well as produce the invention will not increase deadweight
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loss. We discuss how the market test requirement could be
structured and how due diligence milestones and other provisions could be used to discourage gaming.
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INTRODUCTION
The federal government provides over $100 billion in direct
support for scientific research each year—including 47% of all
basic research funding and 37% of all applied research funding
in the United States—most of which goes to universities, other
nonprofits, or federal research institutes.1 Recipients of this
public funding have become increasingly active players in the
1
NAT’L SC. BD., NAT’L SCI. FOUND., SCIENCE & ENGINEERING INDICATORS 2016, at
4–29 tbl.4–3, http://www.nsf.gov/statistics/2016/nsb20161/uploads/1/
nsb20161.pdf [https://perma.cc/X6JW-TXK7].
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U.S. patent system since the Bayh–Dole Act of 1980, which
clarified that they can patent and license federally funded research results to promote commercialization of inventions arising from these results.2 Today, every major U.S. research
institution has a technology transfer office, and the growth in
university patenting and licensing has been praised for “rejuvenating the entire U.S. economic system.”3 A biotechnology lobbying report touts that Bayh–Dole licensees contributed as
much as $1 trillion in sales and up to three million U.S. jobs
between 1996 and 2010.4 Inspired by this success, many other
countries are emulating the U.S. system.5
But the Bayh–Dole Act and its export abroad have also
been subject to a steady undercurrent of academic criticism,
which has emphasized both harm to scientific norms and harm
to the consumers who bear the costs of unnecessary patents.6
There is also increasing public concern about whether univer2
35 U.S.C. §§ 200–212 (2012). The lesser-known Stevenson-Wydler Act of
1980 similarly governs technology transfer by federal laboratories. 15 U.S.C.
§§ 3701–3714 (2012). For the history of patents on publicly funded research and
a critique of these laws, see Rebecca S. Eisenberg, Public Research and Private
Development: Patents and Technology Transfer in Government-Sponsored Research, 82 VA. L. REV. 1663, 1671–95 (1996).
3
Vicki Loise & Ashley J. Stevens, Commentary, The Bayh–Dole Act Turns 30,
2 SCI. TRANSLATIONAL MED. 1, 1 (2010). For simplicity, we use “university patenting” to refer to patenting by universities, nonprofits, or the government. For-profit
firms also receive some direct federal research funding, and a modified version of
our proposal might apply to them, but most of our discussion is specific to the
nonprofit research context. Our proposal might also be compelling for nonBayh–Dole patenting by universities, but we think it is most compelling for inventions that were created with public funding.
4
BIOTECHNOLOGY INDUS. ORG., THE ECONOMIC CONTRIBUTION OF UNIVERSITY/NONPROFIT INVENTIONS IN THE UNITED STATES: 1996–2010, at 3 (2012), http://www.bio.
org/articles/economic-contribution-universitynonprofit-inventions-unitedstates-1996-2010 [https://perma.cc/J4R3-ERBE] (adjusting monetary amounts
for inflation to 2016 dollars); see also Innovation’s Golden Goose, THE ECONOMIST,
Dec. 14, 2002, at 3 (hailing Bayh–Dole as “[p]ossibly the most inspired piece of
legislation to be enacted in America over the past half-century”).
5
See EVITA PARASKEVOPOULOU, THE ADOPTION OF BAYH–DOLE TYPE POLICIES IN
DEVELOPING COUNTRIES (2013), https://www.innovationpolicyplatform.org?/sites/
default/files/rdf_imported_documents/TheAdoptionOfBayhDoleTypePoliciesIn
DevelopingCountries.pdf [https://perma.cc/CF5X-FBXQ].
6
For a summary of criticism in the domestic context, see Lisa Larrimore
Ouellette, Comment, Addressing the Green Patent Global Deadlock Through
Bayh–Dole Reform, 119 YALE L.J. 1727, 1730 & nn.18–20 (2010) [hereinafter
Ouellette, Addressing the Green Patent Global Deadlock]. For critiques of
Bayh–Dole’s global spread, see David C. Mowery & Bhaven N. Sampat, The
Bayh–Dole Act of 1980 and University–Industry Technology Transfer: A Model for
Other OECD Governments?, in ESSAYS IN HONOR OF EDWIN MANSFIELD 233, 241
(Albert N. Link & F.M. Scherer eds., 2005); and Anthony D. So et al., Is Bayh–Dole
Good for Developing Countries? Lessons from the US Experience, 6 PLOS BIO. 2078
(2008).
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sity patent owners are really acting in the public interest. Universities have been criticized for selling their patents to patent
assertion entities, also known as “patent trolls.”7 Boston University was labeled a patent troll itself for its successful suit
against tech giants such as Apple, Microsoft, Amazon, HP, and
Samsung for infringing a patent on gallium nitride films,8 and
this critique has been echoed against other university patent
plaintiffs.9 University patent litigants have won staggering
awards in district court, such as the Wisconsin Alumni Research Foundation’s $234 million award against Apple (appeal
pending)10 and Carnegie Mellon University’s $1.5 billion award
against Marvell Semiconductor (reduced to $750 million in a
settlement).11 One study found “a number of lawsuits in which
university software patents have been used not for purposes of

7
See, e.g., Heidi Ledford, Universities Struggle To Make Patents Pay, 501
NATURE 471, 471 (2013) [hereinafter Ledford, Universities Struggle To Make Patents Pay] (noting criticism of Caltech’s sale of patents to a patent assertion entity).
8
See John Koetsier, Congratulations, Boston University, You’re Now a Patent
Troll, VENTUREBEAT (July 3, 2013, 12:17 PM), http://venturebeat.com/2013/07/
03/congratulations-boston-university-youre-now-a-patent-troll [https://
perma.cc/4B2K-4AWH]. Twenty-five of the companies agreed to undisclosed licensing fees. See Jon Brodkin, Patent-Waving Boston U. Wins Cash from Apple,
Amazon, and Microsoft, ARS TECHNICA (Jan. 16, 2014, 12:45 PM), http://arstechnica.com/tech-policy/2014/01/patent-waving-boston-u-wins-cash-fromapple-amazon-and-microsoft [https://perma.cc/5NLU-AL37]. Boston University
won over $13 million from the remaining three defendants. See Joel Brown, BU
Wins $13 Million in Patent Infringement Suit, BU TODAY (Dec. 7, 2015), http://
www.bu.edu/today/2015/bu-wins-13-million-in-patent-infringement-suit
[https://perma.cc/7CUN-6K7M].
9
See, e.g., Joe Mullin, Public University, Public Research—And Four Big Patent Suits, ARS TECHNICA (Nov. 11, 2014, 9:45 AM), http://arstechnica.com/techpolicy/2014/11/public-university-public-research-and-four-big-patent-suits
[https://perma.cc/BC9B-6LQC] (noting that the “increasing number of patent
lawsuits” filed by U.S. universities “has spawned some criticism that universities
are . . . engag[ing] in litigation strategies similar to that of so-called ‘patent
trolls’”). Mark Lemley was one of the first to identify this sentiment that “universities are the new patent trolls,” though he opined that “the general answer” is that
they are not. Mark A. Lemley, Are Universities Patent Trolls?, 18 FORDHAM INTELL.
PROP. MEDIA & ENT. L.J. 611, 611, 612 n.1 (2008) [hereinafter Lemley, Are Universities Patent Trolls?].
10
See Andrew Chung, Apple Ordered To Pay $234 Million to University for
Infringing Patent, REUTERS (Oct. 16, 2015, 6:58 PM), http://www.reuters.com/
article/us-apple-patent-defense-idUSKCN0SA20E20151016 [https://perma.cc/
RVT6-YKVQ].
11
See Susan Decker, Marvell Technology To Pay $750 Million to Carnegie
Mellon, 91 PAT. TRADEMARK & COPYRIGHT J. (BNA) 1126 (Feb. 19, 2016); Joe Mullin,
Chipmaker Hopes To Overturn Largest Patent Verdict Ever: $1.5 Billion, ARS
TECHNICA (Apr. 10, 2015, 11:51 AM), http://arstechnica.com/tech-policy/2015/
04/chipmaker-hopes-to-overturn-largest-patent-verdict-ever-1-5-billion [https:/
/perma.cc/A9ZY-BXXY].

\\jciprod01\productn\C\CRN\102-2\CRN201.txt

2017]

unknown

Seq: 5

17-JAN-17

A MARKET TEST FOR BAYH–DOLE PATENTS

10:50

275

fostering commercialization, but instead to extract rents in apparent holdup litigation.”12
When a university seeks to nonexclusively license its patents to firms that are already using the technology and sues
unwilling firms for infringement, it is hard to see how
Bayh–Dole is fulfilling its statutory goal of “promot[ing] the utilization of inventions arising from federally supported research
or development.”13 The inventions at issue already were being
used by firms who lack exclusive rights to those patents—otherwise there would have been nothing to sue over—indicating
that such exclusivity was not required for commercialization.
And the same logic applies when a university charges to license
an invention nonexclusively, such as for the acclaimed Cohen–Boyer patents on early recombinant DNA technology that
brought in $255 million in licensing fees for Stanford.14 The
Cohen–Boyer patents are not an anomaly.15 University technology transfer offices grant more nonexclusive licenses than
exclusive ones,16 and some commentators have argued for even
wider use of nonexclusive licensing.17 We think, to the con12
Arti K. Rai, John R. Allison, & Bhaven N. Sampat, University Software
Ownership and Litigation: A First Examination, 87 N.C. L. REV. 1519, 1519 (2009).
13
35 U.S.C. § 200 (2012).
14
See Kirsten Leute, Patenting and Licensing of University-Based Genetic
Inventions—A View from Experience at Stanford University’s Office of Technology
Licensing, 8 COMMUNITY GENETICS 217, 221 (2005). As Rebecca Eisenberg has
explained, “[I]t can hardly be argued that the[se] patents have done anything to
promote product development that would not have occurred if the patented technology had instead been placed in the public domain.” Eisenberg, supra note 2, at
1710.
15
See, e.g., David C. Mowery et al., The Growth of Patenting and Licensing by
U.S. Universities: An Assessment of the Effects of the Bayh–Dole Act of 1980, 30
RES. POL’Y 99, 118 (2001) (concluding that “[i]n the[ ] three universities [studied],
biotechnology research tools have been licensed widely,” but noting that “this
practice does not spur technology transfer” and instead simply provides a new
source of revenue for the university).
16
The percentage of nonexclusive licenses out of the thousands of licenses
reported each year on an annual survey of technology transfer offices was 60 to
65% from 2009 through 2013. Statistics Access for Technology Transfer (STATT)
Database, ASS’N OF UNIV. TECH. MANAGERS, http://www.autm.net/resourcessurveys/research-reports-databases/statt-database-(1) [https://perma.cc/
4CXC-VG7F] (proprietary database). The database does not disclose the amount
of income received from the two types of licenses.
17
See, e.g., Bryan Collinsworth & Sara E. Crager, Should Academic Therapeutic Patents Go to the Highest Bidder?, 24 EXPERT OPINION ON THERAPEUTIC PATENTS
481, 483 (2014) (“[M]any university innovations have been successfully licensed
on a nonexclusive basis, and we advocate incentivizing such licensing as the
‘default’ approach . . . .”); Martin Kenney & Donald Patton, Reconsidering the
Bayh–Dole Act and the Current University Invention Ownership Model, 38 RES.
POL’Y 1407, 1414, 1417–18 (2009) (proposing a mandatory nonexclusive licensing
model for university patent ownership); Lemley, Are Universities Patent Trolls?,
supra note 9, at 626 (noting that, at times, a nonexclusive license will maximize
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trary, that if the conventional wisdom is correct that Bayh–Dole
patents are justified only by their commercialization incentive,18 then a nonexclusive license is prima facie evidence that
the invention ought not to have been patented at all.19
The genius of Bayh–Dole, in the words of The Economist, is
that it gives firms the exclusive rights needed “to invest millions
more of their own money to turn a raw research idea into a
marketable product” rather than leaving university inventions
“in warehouses gathering dust.”20 There is no question that
university technology transfer can create enormous value and
that the Bayh–Dole system is an improvement on the prior
system of uncertain patent rights in government hands.21 The
success of Silicon Valley can be attributed in part to Stanford’s
encouragement of faculty or students who wanted to commercialize inventions created with university resources; companies
spawned include Hewlett-Packard, Cisco, Yahoo!, Sun
Microsystems, and Google (for which Larry Page’s web-crawling
efforts at one point used almost half of Stanford’s internet
bandwidth).22 In some cases, exclusivity is needed to incentivize entrepreneurs and inventors to take a risk on a new idea
that would otherwise gather dust. (This may have been the
case for Google’s foundational patents, which established companies such as Yahoo!, Excite, and AltaVista were uninterested
in licensing.23) But this commercialization rationale for exclusive patents on publicly funded inventions makes little sense

an invention’s impact on society); Carolyn L. Treasure et al., What Is the Public’s
Right To Access Medical Discoveries Based on Federally Funded Research?, 311
JAMA 907, 908 (2014) (arguing that “[i]f universities issued more nonexclusive
licenses” it would increase access to health technologies and that “legislative
strategies may be needed to incentivize nonexclusive licensing”).
18
See infra Part I.
19
A caveat to this is that if the nonexclusive license is only offered to a small
number of firms or otherwise has an appreciable effect on quantity, then it may
have similar benefits (and costs) as an exclusive license.
20
Innovation’s Golden Goose, supra note 4.
21
For a thorough history of university patenting, including discussion of the
Institutional Patent Agreements that allowed universities to take title to patents
even before the Bayh–Dole Act, see generally Peter Lee, Patents and the University,
63 DUKE L.J. 1 (2013) [hereinafter Lee, Patents and the University].
22
See WALTER ISAACSON, THE INNOVATORS 450, 457 (2014); see also MARIANA
MAZZUCATO, THE ENTREPRENEURIAL STATE: DEBUNKING PUBLIC VS. PRIVATE SECTOR
MYTHS (2015) (discussing the key role of federal funds in the development of
numerous breakthrough technologies).
23
See ISAACSON, supra note 22, at 462.
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when numerous firms are already eager to use the inventions
without exclusivity.24
Federal agencies do have legal tools to prevent abuse of
university patents. The Bayh–Dole Act allows agencies to exercise “march-in rights” to compel licensing of university patents
if necessary to make the invention “available to the public on
reasonable terms” or “to alleviate health or safety needs,”25 and
“in exceptional circumstances” an agency may determine “that
restriction or elimination of the [patent] right . . . will better
promote the policy and objectives of” the Act.26 These rights
have never been exercised.27 But given recent concern about
the high price of pharmaceuticals and the substantial role universities play in basic drug discovery—one study found that
about a quarter of new drugs approved from 1998 to 2007
originated in universities28—over fifty members of the House of
Representatives recently (albeit unsuccessfully) urged the National Institutes of Health (NIH) to exercise their march-in
rights.29
The problem with more frequent exercise of march-in
rights, however, is that exclusive patent rights often are necessary to drive commercialization, particularly in the biomedical
context. Pharmaceutical companies will not undertake the significant expense of clinical trials if they do not have sufficient

24
We are not the first to make this observation. See, e.g., Eisenberg, supra
note 2, at 1710; Arti Kaur Rai, Regulating Scientific Research: Intellectual Property
Rights and the Norms of Science, 94 NW. U. L. REV. 77, 120, 135 (1999).
25
35 U.S.C. §§ 201(f), 203(a)(1)–(2) (2012).
26
35 U.S.C. § 202(a)(ii). Furthermore, the government retains a paid-up,
nonexclusive license to practice inventions covered by the Act. 35 U.S.C.
§ 202(c)(4).
27
See Ryan Whalen, Note, The Bayh–Dole Act & Public Rights in Federally
Funded Inventions: Will the Agencies Ever Go Marching in?, 109 NW. U. L. REV.
1083, 1083 (2015).
28
Robert Kneller, The Importance of New Companies for Drug Discovery: Origins of a Decade of New Drugs, 9 NATURE REVIEWS DRUG DISCOVERY 867, 869
(2010).
29
Letter from Lloyd Doggett, U.S. Rep., et al. to Sylvia Mathews Burwell,
Sec’y, U.S. Dep’t of Health & Human Servs., & Francis S. Collins, Dir., Nat’l Insts.
of Health (Jan. 11, 2016), http://keionline.org/sites/default/files/Doggett-51
member-MarchIn-11Jan2016.pdf [https://perma.cc/J4EF-RZ4Y]; see John M.
Clerici & Phillip Bradley, Federal Gov’t Won’t March in When It Comes to Drug
Prices, LAW 360 (July 11, 2016, 4:36 PM), http://www.law360.com/articles/
815909/federal-gov-t-won-t-march-in-when-it-comes-to-drug-prices [https://
perma.cc/N3EV-LDG5]. Another option would be to use 28 U.S.C. § 1498, which
allows government use of any U.S. patent in exchange for reasonable compensation. See Hannah Brennan et al., A Prescription for Excessive Drug Pricing: Leveraging Government Patent Use for Health, 18 YALE J.L. & TECH. 275, 319–21 (2016).
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patent rights on the compound of interest,30 and the need for a
lengthy exclusivity period skews medical research toward diseases for which clinical trials can be conducted more quickly.31
(Of course, patents are only one of many policy tools to correct
market failures at different stages of the R&D process—to the
extent firms have insufficient incentives for commercialization,
governments can and do use commercialization grants, tax incentives, or prizes, and these alternative tools often might be
superior.32 But here we focus on improving rather than replacing Bayh–Dole.)
So when are exclusive patent rights actually necessary to
induce commercialization? A technology for which the answer
to this question is nonobvious is the gene-editing technique
known as CRISPR, which has been called “the biggest biotechnology advance since the polymerase chain reaction” (a DNAcopying technique developed in 1983).33 The CRISPR technology is currently subject to what Professor Jacob Sherkow calls
“an absolutely humungous biotech patent dispute” over who
gets priority: a group at the University of California at Berkeley,
or a different group at the Broad Institute of Harvard and
MIT.34 Berkeley and the Broad Institute have granted different
startups exclusive rights to their CRISPR patents for therapeutic purposes, so the priority battle may determine which star-

30
See Benjamin N. Roin, Unpatentable Drugs and the Standards of Patentability, 87 TEX. L. REV. 503, 545–47 (2009). For a summary of the economics of
drug development and the importance of patents in the pharmaceutical industry,
see Lisa Larrimore Ouellette, How Many Patents Does It Take To Make a Drug?
Follow-on Pharmaceutical Patents and University Licensing, 17 MICH. TELECOMM. &
TECH. L. REV. 299, 302–03 (2010) [hereinafter Ouellette, How Many Patents Does It
Take To Make a Drug?].
31
See Eric Budish, Benjamin N. Roin, & Heidi Williams, Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials, 105 AM. ECON.
REV. 2044, 2045–50 (2015). Patents used to be less important to university–industry collaborations, but demand for exclusive licenses to NIH-sponsored
inventions grew in the 1960s in response to regulatory changes that increased the
cost of bringing new drugs to market. See Roberto Mazzoleni, Before Bayh–Dole:
Public Research Funding, Patents, and Pharmaceutical Innovation (1945–1965), 20
INDUS. & CORP. CHANGE 721, 724 (2011).
32
See Daniel J. Hemel & Lisa Larrimore Ouellette, Beyond the Patents–Prizes
Debate, 92 TEX. L. REV. 303, 314 (2013) [hereinafter Hemel & Ouellette, Beyond
the Patent–Prizes Debate] (comparing these mechanisms); see also Camilla A.
Hrdy, Commercialization Awards, 2015 WIS. L. REV. 13, 51–72 (reviewing government incentives for commercialization outside the patent system, particularly at
the state and local level).
33
Heidi Ledford, Bitter Fight over CRISPR Patent Heats Up, 529 NATURE 265,
265 (2016).
34
Id. (quoting Professor Jacob Sherkow, New York Law School).
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tup survives.35 But is exclusivity really necessary for the
development of gene-editing therapeutics, or would it better
serve the public interest to have multiple firms entering this
space, without the constraint of a patent on the fundamental
technique? Is there some way to tell whether CRISPR is more
like the small-molecule pharmaceuticals for which exclusive
rights clearly are needed or more like Boston University’s gallium nitride films and Stanford’s basic recombinant DNA techniques, for which patents seem to merely create unnecessary
deadweight loss?36
In this Article, we argue that the answer is “yes.” In particular, we propose a “market test” for federally funded inventions
at universities and other nonprofits.37 In short, before exclusively licensing these inventions for the full remaining patent
term, federal grant recipients would be required to offer the
invention under a nonexclusive license for a nominal fee to
cover the costs of patent acquisition.38 If a company will develop the invention under a nonexclusive license, then the uni35
See Jenny Rood, Who Owns CRISPR?, THESCIENTIST (Apr. 3, 2015), http://
www.the-scientist.com/?articles.view/articleNo/42595/title/Who-OwnsCRISPR- [https://perma.cc/JU9M-F6HL].
36
Mark Lemley has argued that the pharmaceutical and biotechnology industries are a special case “because of the regulatory barriers to entry” that make
it very expensive to bring a product to market and comparatively cheap to imitate
it, and that “[i]n the IT industries, and even in industries like medical devices,
there is no reason to believe that exclusive rights are necessary to encourage
commercialization.” Lemley, Are Universities Patent Trolls?, supra note 9, at 624.
For a summary of why patents are less likely to be necessary for commercialization in engineering fields (and might in fact hinder the spread of these technologies), see Ouellette, Addressing the Green Patent Global Deadlock, supra note 6, at
1731–32. But we think there is no strong reason to believe that exclusive rights
are not necessary to encourage commercialization for at least some inventions in
these fields. For a review of the ambiguous evidence on the extent to which
patents are needed for different purposes, see Lisa Larrimore Ouellette, Patent
Experimentalism, 101 VA. L. REV. 65, 75–87 (2015) [hereinafter Ouellette, Patent
Experimentalism].
37
We focus on federally funded inventions at universities because this seems
like the clearest test ground for our proposal, both analytically and politically. If
our market test is successful in this context, it is worth considering whether it
should be applied to university patenting more broadly (for example, inventions
that are funded by state grants, foundations, or even for-profit firms) and whether
it should be applied to federally funded inventions more broadly (including grants
received by private, for-profit firms). Our market test could also be applied in
other contexts in which commercialization is the main reason for granting patents. Not all of our discussion below applies with equal force to all of these
contexts.
38
To reduce administrative costs, the optimal approach may be to allow this
mechanism to be triggered by an interested licensee. See infra notes 145, 214 and
accompanying text. Our proposal would thus only affect patents that numerous
firms are eager to license—which may be a small fraction of all university patents,
but which likely contribute disproportionately to social cost.
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versity should be required to offer free nonexclusive licenses to
anyone else who wants to practice the invention. Market evidence that a firm is willing to commercialize the invention without the benefit of being able to constrain quantity should
preclude grant recipients from using an exclusive license—or
any nonexclusive license that leads to quantity constraints.39
Our argument proceeds in three parts. In Part I, we explain why commercialization theory is currently the dominant
justification for Bayh–Dole patents, and we set out the challenge of determining whether exclusive patent grants are necessary to incentivize commercialization. Part II describes our
market test in more detail. We show that deadweight loss can
be reduced through an auction that forces bidders to reveal the
least amount of exclusivity needed to induce commercialization, that revenue cap bidding is more efficient than duration
bidding (though perhaps less administratively feasible), and
that defensive bidding by firms that consume as well as produce the invention will not increase deadweight loss. Finally,
Part III explores how different actors—universities, grant agencies, and Congress—might help implement this market test of
exclusivity for Bayh–Dole patents, and how due diligence milestones and other provisions can be used to discourage gaming.
By showing that it would not be infeasible to limit Bayh–Dole
patents to those areas in which they are actually needed for
commercialization, we hope to shift the burden to Bayh–Dole
defenders to develop stronger theoretical and empirical accounts of why patents should be allowed in other cases.
I
THE PROBLEM: WHICH FEDERALLY FUNDED INVENTIONS SHOULD BE
PATENTED AND EXCLUSIVELY LICENSED?
In the Introduction, we claimed that under the conventional account of the Bayh–Dole Act, universities are not acting
in the public interest when they bring patent lawsuits against
firms who have commercialized the technologies without owning the exclusive rights, or even when they broadly license their
technologies under nonexclusive licenses. In subpart I.A, we
describe how this claim follows from the commercialization
39
As we discuss in Part I, there are other potential justifications for a quantity-constraining license besides commercialization theory, although these have
not been emphasized as much in the Bayh–Dole debates. We are agnostic on
whether any of these benefits might outweigh the costs of exclusivity, but we note
that justifying exclusive Bayh–Dole patents on these grounds would require a
substantial reworking of Bayh–Dole theory and practice.
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theory of Bayh–Dole, and we discuss the other theories that
might be developed further to justify Bayh–Dole patents that
are unnecessary for commercialization. Subpart I.B then turns
to the problem of identifying when exclusive patent rights are
unnecessary for commercialization and thus harmful to the
public interest under the standard account.
A. Economic Justifications for Patents in the University
Context
Patents have significant social costs. Most obviously, patents create deadweight loss because they are effective only to
the extent they give patentees some market power that allows
prices to be raised above marginal cost.40 (Because patents
effectively function as a concentrated sales tax on patented
goods, this deadweight loss is generally higher than the deadweight loss of providing a similar incentive through broadbased taxation.41) Patents also can impede cumulative innovation,42 and they create substantial administrative and enforcement costs.43 In the university context, while patents do not
directly impede subsequent academic research (because academics tend to ignore patents and are rarely sued for infringement),44 patents do appear to impede access to physical

40
See N. GREGORY MANKIW ET AL., PRINCIPLES OF ECONOMICS 310–13 (7th ed.,
2014) (introducing these concepts); Mark A. Lemley, Property, Intellectual Property, and Free Riding, 83 TEX. L. REV. 1031, 1059 [hereinafter Lemley, Free Riding]
(“By definition, therefore, the intellectual property system permits owners to raise
price above marginal cost, creating deadweight losses by raising the price to
consumers.”).
41
See Hemel & Ouellette, Beyond the Patents–Prizes Debate, supra note 32,
at 314–15 (describing the patent “shadow tax” and explaining why the deadweight
loss of monopoly is generally greater than the deadweight loss of income taxation).
42
Measuring the extent to which patents in fact impede cumulative innovation in different contexts is challenging, but for a clever empirical study that
concludes that “on average gene patents have had no effect on follow-on innovation.” Bhaven Sampat & Heidi L. Williams, How Do Patents Affect Follow-on
Innovation? Evidence from the Human Genome 1 (Oct. 13, 2015) (unpublished
manuscript), http://economics.mit.edu/files/10782 [https://perma.cc/8GT3H345].
43
See Lemley, Free Riding, supra note 40, at 1059–64 (describing these and
other costs); see also Hemel & Ouellette, Beyond the Patent–Prizes Debate, supra
note 32, at 364–65 (roughly estimating the administrative costs of the patent
system at $10 billion per year, most of which is paid by private parties).
44
See Lisa Larrimore Ouellette, Note, Access to Bio-Knowledge: From Gene
Patents to Biomedical Materials, 2010 STAN. TECH. L. REV. N1 ¶41 (2010) [hereinafter Ouellette, Access to Bio-Knowledge] (noting that scientists “typically ignore
patents and are rarely sued”).
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materials such as cell lines,45 and they may have other negative effects on the practice and norms of science.46
From a social welfare perspective, patents thus should be
granted only when they produce some benefit that outweighs
these costs. Here, we first explain why the traditional justification for patents—that they provide ex ante incentives to invent—has so far been considered less persuasive in the
university context. We then turn to what has been widely recognized as the more compelling argument for patents on federally funded inventions: that the patents provide ex post
incentives to commercialize.47
Finally, we note four other benefits that university patents
might bring: increased disclosure and signaling about the underlying inventions; increased revenue for the university; the
ability to internalize foreign benefits from U.S. spending on
grants; and the ability to use copyleft-style patent licenses to
prevent unnecessary constraints on certain technologies. In
some cases, a combination of all the benefits we discuss may
outweigh the costs of exclusivity, even where exclusivity is unnecessary for commercialization. But these alternative benefits
are not why the Bayh–Dole Act was enacted and have not been
the foundation of the policy debates surrounding Bayh–Dole. If
exclusive patent rights are to be justified on these grounds, it
would require a rethinking of both Bayh–Dole theory and
practice.48

45
See generally id. (citing numerous empirical studies, primarily based on
survey results).
46
See Jeremy M. Grushcow, Measuring Secrecy: A Cost of the Patent System
Revealed, 33 J. LEGAL STUD. 59, 75–79 (2004); Wei Hong & John P. Walsh, For
Money or Glory? Commercialization, Competition, and Secrecy in the Entrepreneurial University, 50 SOC. Q. 145, 147–49 (2009); Rai, supra note 24, at
85–86.
47
See Eisenberg, supra note 2, at 1668–69; Lemley, Are Universities Patent
Trolls?, supra note 9, at 621; Rai, supra note 24, at 97–99; see also NAT’L RES.
COUNCIL NAT’L ACADS., MANAGING UNIVERSITY INTELLECTUAL PROPERTY IN THE PUBLIC
INTEREST 60 (2011) (“The first goal of university technology transfer involving IP is
the expeditious and wide dissemination of university-generated technology for the
public good.”).
48
One of us is separately considering a number of these underappreciated
benefits of Bayh–Dole. See generally Daniel J. Hemel & Lisa Larrimore Ouellette,
Bayh–Dole Beyond Borders (unpublished manuscript) (Sept. 1, 2016) (on file with
authors) [hereinafter Hemel & Ouellette, Bayh–Dole Beyond Borders]; Daniel J.
Hemel & Lisa Larrimore Ouellette, Innovation Policy Pluralism (Aug. 7, 2016)
(unpublished manuscript) (on file with authors) [hereinafter Hemel & Ouellette,
Innovation Policy Pluralism].
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1. Ex Ante Innovation Incentives
The traditional justification for patent laws is that they
provide ex ante incentive to innovate by allowing ex post recovery of research costs (including associated risks).49 But as Rebecca Eisenberg writes, this argument “loses much of its force
in the case of inventions made with public funding” where taxpayers have already “absorbed the risk that nothing would
come of [their] investment.”50 Federal grants typically cover the
fixed costs of a given research project and the public bears the
risk of failure, so there is no obvious need to allow grant recipients to charge supra-competitive prices to recoup their costs.51
Bayh–Dole scholars have noted that grant recipients already
have strong incentives to innovate, including the desire for tenure and promotion, awards, and prestige.52 Perhaps even more
directly, grant recipients receive money to pursue particular
projects and must report on their results,53 and they are unlikely to receive additional grants if they do not successfully
follow through with earlier projects. Grants are critical for supporting graduate students and postdoctoral associates, for
purchasing laboratory equipment, and often for funding part of
the principle investigator’s salary—a more immediate financial
concern than speculative patent royalties. Unlike scientists at
private firms, university scientists generally must raise all of
the capital necessary to support their research before spending
it; there is not currently a market for loans to academic scientists that might be paid back through patent royalties.54
49
See, e.g., STAFF OF SUBCOMM. ON PATENTS, TRADEMARKS & COPYRIGHTS OF THE
S. COMM. ON THE JUDICIARY, 85TH CONG., AN ECONOMIC REVIEW OF THE PATENT SYSTEM,
STUDY NO. 15, at 33 (Comm. Print 1958) (prepared by Professor Fritz Machlup)
[hereinafter Machlup Report] (stating that the “widely accepted” and “fundamental
economic justification of patents” is “to encourage inventing”); Mark A. Lemley, Ex
Ante Versus Ex Post Justifications for Intellectual Property, 71 U. CHI. L. REV. 129,
129 (2004) (“The standard justification for intellectual property is ex ante . . . . It
is the prospect of the intellectual property right that spurs creative incentives.”).
50
Eisenberg, supra note 2, at 1668.
51
See generally Hemel & Ouellette, Beyond the Patents–Prizes Debate, supra
note 32, at 333–44 (comparing ex ante incentives like grants to ex post incentives
like patents).
52
See Lemley, Are Universities Patent Trolls?, supra note 9, at 621.
53
See, e.g., Meeting NSF’s Technical Reporting Requirements, NAT’L SCI.
FOUND. (May 22, 2013), http://www.nsf.gov/pubs/2013/nsf13094/nsf13094.jsp
[https://perma.cc/Y975-S6JT]; Report Catalog, NAT’L INSTS. OF HEALTH, https://
report.nih.gov/catalog.aspx [https://perma.cc/A89N-ZLAU].
54
Cf. Hemel & Ouellette, Beyond the Patents–Prizes Debate, supra note 32, at
334–39 (discussing the disadvantage of providing ex post incentives like patents
and prizes when researchers face capital constraints).
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We do not mean to imply that the ex ante justification for
patents loses all of its force in the university context. Patents
may help compensate researchers for the opportunity cost of
their time, encouraging them to stay in science rather than
pursuing more lucrative careers in finance.55 And more money
may mean more research: the added incentive of a potential
patent payout could provide enough extra incentive to university researchers to be worth the associated deadweight loss.56
Indeed, mixing patents and grants may help direct researchers’
efforts toward those projects that are the most socially beneficial.57 But these theories have not been the justifications offered by Bayh–Dole proponents, and so far, they lack any clear
supporting evidence. There is evidence that patent royalties
matter in at least some respects: economists Saul Lach and
Mark Schankerman have demonstrated that universities that
provide faculty scientists with a larger percentage of patent
royalties generate greater licensing income.58 But there is no
evidence yet that the patent incentive increases research outputs, rather than simply creating a greater incentive for faculty
to pursue lucrative licenses or directing scientists toward more
applied projects (which might have additional negative social
effects).59
Qualitative evidence suggests that academic scientists are
most concerned about maximizing their credibility and reputation, and that patents are valued to the extent they are viewed
as enhancing credibility. The oft-cited work of sociologist Robert Merton focuses on idealized norms such as disinterestedness and communalism.60 Others have criticized this
romanticized view and argued that academic scientists are bet55
Cf. Landon Thomas Jr., Traders with Ph.D.s, N.Y. TIMES, Feb. 23, 2016, at
B1, B4 (“Harnessing Ph.D.-toting mathematicians to the most powerful computers money can buy has become the accepted way for hedge funds and banks to
get a trading edge these days . . . .”).
56
See Hemel & Ouellette, Innovation Policy Pluralism, supra note 48 (manuscript at 17–18) (examining this theory).
57
See id. The consequences of mixing are not necessarily positive.
58
Saul Lach & Mark Schankerman, Incentives and Invention in Universities,
39 RAND J. ECON. 403, 404–405 (2008); Saul Lach & Mark Schankerman, Royalty
Sharing and Technology Licensing in Universities, 2 J. EUR. ECON. ASS’N 252, 257
(2004).
59
One study of invention disclosures from eight U.S. universities from 1983
to 1999 casts some doubt on the hypothesis that Bayh–Dole diverted scientists
from more “basic” research. Jerry G. Thursby & Marie C. Thursby, Has the
Bayh–Dole Act Compromised Basic Research?, 40 RES. POL’Y 1077, 1081 (2011).
60
E.g., ROBERT K. MERTON, THE SOCIOLOGY OF SCIENCE (1973) (discussing scientific norms generally); Robert K. Merton, Priorities in Scientific Discovery: A Chapter in the Sociology of Science, 22 AM. SOC. REV. 635, 639 (1957) (discussing
historical trends in scientific disputes over priority of discovery).
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ter viewed as rational strategists who seek to maximize credibility, which is measured through both concrete metrics such
as publications and grants as well as more intangible markers
of prestige.61 Under either view, patents are not a significant
goal. More recent survey work also suggests that the financial
incentive from patent royalties plays a small role in academic
scientists’ motivations and that a scientist’s sentiments toward
patenting are strongly guided by how her department values
entrepreneurial activity.62
It is even theoretically possible that the financial incentive
from potential patent royalties may decrease ex ante innovation incentives for university scientists. Yochai Benkler has
argued that innovators are commonly motivated by “social-psychological rewards” and that extrinsic financial rewards may
“crowd out” intrinsic motivations.63 For some academic scientists, the increased focus on profits in university research may
decrease their other incentives for generating new knowledge,
resulting in a smaller total incentive per dollar transferred from
the public.
In sum, there is no strong evidence indicating whether
Bayh–Dole skews ex ante incentives toward projects with either
higher or lower social value. And there is certainly no evidence
that any marginal gain in ex ante incentives is worth the subsequent deadweight loss in making the public “pay twice” for
these inventions.64 This may well change, either due to new
61

See, e.g., BRUNO LATOUR & STEVE WOOLGAR, LABORATORY LIFE: THE CONSTRUCSCIENTIFIC FACTS 187–201 (1986) (arguing that scientists are often motivated by a desire for credibility); S.B. Barnes & R.G.A. Dolby, The Scientific Ethos:
A Deviant Viewpoint, 11 EUR. J. SOC. 3, 7 (1970) (arguing that Merton’s approach
fails to identify constant normative structures within scientific activity); Michael
J. Mulkay, Norms and Ideology in Science, 15 SOC. SCI. INFO. 637, 641 (1976)
(discussing critiques of Merton’s work and providing counterexamples). For an
excellent discussion of how Bayh–Dole debates should incorporate this nonMertonian work, see Tai-Jan Huang, Beyond Patent Royalties: Putting Academic
Scientists Back into the Bayh–Dole Debate (Jan. 6, 2016) (unpublished manuscript) (on file with authors).
62
See Alice Lam, What Motivates Academic Scientists to Engage in Research
Commercialization: ‘Gold’, ‘Ribbon’ or ‘Puzzle’?, 40 RES. POL’Y 1354, 1366 (2011);
Brian J. Love, Do University Patents Pay Off? Evidence from a Survey of University
Inventors in Computer Science and Electrical Engineering, 16 YALE J.L. & TECH.
285, 286 (2014); Jason Owen-Smith & Walter W. Powell, To Patent or Not: Faculty
Decisions and Institutional Success at Technology Transfer, 26 J. TECH. TRANSFER
99, 102 (2001); Catherine Searle Renault, Academic Capitalism and University
Incentives for Faculty Entrepreneurship, 31 J. TECH. TRANSFER 227, 229 (2006).
63
YOCHAI BENKLER, THE WEALTH OF NETWORKS: HOW SOCIAL PRODUCTION TRANSFORMS MARKETS AND FREEDOM 92–98 (2006).
64
The concern that Bayh–Dole makes the public “pay twice” is one of the
most frequent critiques of Bayh–Dole. See, e.g., Bd. of Trs. of Leland Stanford Jr.
Univ. v. Roche Molecular Sys., 131 S. Ct. 2188, 2201 (2011) (Breyer, J., dissentTION OF
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empirical work or to changes in university research practices.
For example, perhaps some university research will move to a
model in which research grants reimburse only a small percentage of the costs of inventing.65 Indeed, we hope this Article
will inspire Bayh–Dole defenders to think more seriously about
how to best justify patents on federally funded inventions in
those cases when they are unnecessary for commercialization.
But for now, given the certain costs that must be incurred to
receive what is at best a speculative benefit, ex ante incentives
are not a compelling justification for university patents.66
2. Ex Post Commercialization
The more convincing justification for university patents is
that they provide an ex post incentive to commercialize inventions that would otherwise sit “in warehouses gathering
dust.”67 Ex post theories have a long history in debates over
the economics of patenting, even outside the university context. Indeed, Fritz Machlup’s famous 1958 review of the patent
system gives preeminent status to ex post theories:
The thesis that patent protection is needed as a stimulus to
invention has been first supplemented and then replaced by
the thesis that it is needed as a stimulus to the practical use
of new inventions in industry. Financing the work that leads
to the making of an invention may be a relatively small venture compared with that of financing its introduction, because costly development work, experimentation in
production and experimentation in marketing may be needed
before the commercial exploitation of the invention can begin.
The risks involved may be too great to be undertaken except
under the shelter of a monopoly grant.68
ing); Rochelle Cooper Dreyfuss, Collaborative Research: Conflicts on Authorship,
Ownership, and Accountability, 53 VAND. L. REV. 1161, 1194 (2000); Eisenberg,
supra note 2, at 1666; Bhaven N. Sampat & Frank R. Lichtenberg, What Are the
Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?,
30 HEALTH AFF. 332, 333 (2011).
65
Cf. Suzanne Scotchmer, Patents in the University: Priming the Pump and
Crowding Out, LXI J. INDUS. ECON. 817, 842 (2013) (proposing a requirement of
university matching for grant awards, and noting that “the federal government
does not give funds on this basis”).
66
Indeed, a discussion of many benefits of Bayh–Dole by Stanford’s technology transfer office does not even attempt to argue that the patent incentive will
cause academics to produce more or better research. See Hans Wiesendanger, A
History of OTL: Overview, STANFORD UNIV. OFFICE OF TECH. LICENSING (2000), http://
otl.stanford.edu/about/about_history.html [https://perma.cc/9K2L-KFRA].
67
Innovation’s Golden Goose, supra note 4; see also Chester G. Moore, Killing
the Bayh–Dole Act’s Golden Goose, 8 TUL. J. TECH. & INTELL. PROP. 151, 155–56
(2006) (concurring with The Economist’s assessment).
68
See Machlup Report, supra note 49, at 36–37.
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This ex post function has since been promoted and explored in
great detail by numerous legal scholars.69
The commercialization argument takes on even more significance in the university context (where ex ante incentives are
less important), and this focus is expressly stated in the text of
the Bayh–Dole Act. The first-listed goal in the statute is “to
promote the utilization of inventions arising from federally supported research or development,” and another goal is to “protect the public against nonuse . . . of inventions.”70 The
legislative history also focuses on commercialization. Senator
Birch Bayh was concerned with the “[h]undreds of valuable
medical, energy, and other technical discoveries” that were “sitting unused.”71 The House Report specified that the goal of the
Act was to “encourage private industry to utilize government
funded inventions through the commitment of the risk capital
necessary to develop such inventions to the point of commercial application.”72 As explained in a Congressional Research
Service report reviewing the rationale of the Bayh–Dole Act, “it
was widely argued that without title (or at least an exclusive
license) to an invention and the protection it conveys, a company would not invest the additional, and often substantial
time and money necessary to commercialize a product or pro-

69
See generally Michael Abramowicz, The Danger of Underdeveloped Patent
Prospects, 92 CORNELL L. REV. 1065 (2007) (discussing the problem of insufficient
remaining patent term to incentivize ex post commercialization); Michael
Abramowicz & John F. Duffy, Intellectual Property for Market Experimentation, 83
N.Y.U. L. REV. 337, 396–408 (2008) [hereinafter Abramowicz & Duffy, Market
Experimentation] (discussing the role of patents in encouraging post-patenting
commercialization and market experimentation); F. Scott Kieff, Property Rights
and Property Rules for Commercializing Inventions, 85 MINN. L. REV. 697, 703
(2001) (“[T]he treatment of patents as property rights is necessary to facilitate
investment in the complex, costly, and risky commercialization activities required
to turn nascent inventions into new goods and services.”); Edmund W. Kitch, The
Nature and Function of the Patent System, 20 J.L. & ECON. 265, 276–77 (1977)
(discussing the importance of patents for incentivizing commercialization); Ted
Sichelman, Commercializing Patents, 62 STAN. L. REV. 341 (2010) (arguing that
patents are important for, and yet often insufficient for, commercializing inventions, and proposing a new form of commercialization patent). For a critique of ex
post theories, see Lemley, supra note 49, at 131–32.
70
35 U.S.C. § 200 (2012). Other goals are to encourage small businesses,
domestic manufacture, and industry–university collaborations. The statute also
recognizes the value of competition and of unimpeded cumulative innovation with
the goal of “promot[ing] free competition and enterprise without unduly encumbering future research.”
71
124 CONG. REC. 29,122 (1978) (statement of Sen. Bayh).
72
H.R. REP. NO. 96-1307, pt. 1, at 3 (1980).
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cess for the marketplace.”73 Relatedly, Bayh–Dole proponents
argue that patents are needed to encourage university researchers to transfer their tacit knowledge to industry.74
A central concern motivating Bayh–Dole is that without
patent protections there would be a “first-commercializer disadvantage.”75 Without the patent protection offered by an exclusive license, the first firm to commercialize would worry that
it would not be able to recoup the fixed costs of its commercialization because competitors would subsequently enter, free-riding on its commercialization efforts, and drive the price down to
the marginal cost of practicing the now-commercialized invention. When a substantial first-commercialization disadvantage
exists, no firm in an industry might be willing to bring to market socially valuable inventions without some way to limit competitors from free-riding on their commercialization efforts.
Hearings on the bill noted just these kinds of non-commercialization examples such as the federal government’s unsuccessful
effort to convince firms to commercialize penicillin despite the
lack of patent protection, until World War II finally spurred the
government to commercialize the drug itself.76 Arguments
against the bill also illustrate that commercialization was the
primary goal.77
Defenders of the current Bayh–Dole system continue to
emphasize commercialization. Justice Breyer has asserted
that Bayh–Dole patents are only worth their significant cost for
“a special public policy reason”: the Act “seeks to encourage
[grant recipients] to commercialize inventions that otherwise
73
WENDY H. SCHACHT, CONG. RESEARCH SERV., RL32076, THE BAYH–DOLE ACT:
SELECTED ISSUES IN PATENT POLICY AND THE COMMERCIALIZATION OF TECHNOLOGY 2
(2012).
74
See Rai et al., supra note 12, at 1550–51 (“Another major argument often
advanced in favor of patents is that the prospect of licensing royalties induces
university researchers to work with industry licensees and thereby transfer tacit
knowledge necessary for commercialization.”).
75
Cf. Abramowicz & Duffy, Market Experimentation, supra note 69, at 378
(discussing the “first-mover” disadvantage).
76
See University and Small Business Patent Procedures Act: Hearing on S.
414 Before the S. Comm. on the Judiciary, 96th Cong. 146–47 (1979) (testimony of
Dr. Betsy Ancker-Johnson, Vice President, Gen. Motors, Envtl. Activities Staff); id.
at 179 (testimony of Frederick N. Andrews, Vice President for Research, Purdue
Univ.).
77
See, e.g., Peter S. Arno & Michael H. Davis, Why Don’t We Enforce Existing
Drug Price Controls? The Unrecognized and Unenforced Reasonable Pricing Requirements Imposed upon Patents Deriving in Whole or in Part from Federally
Funded Research, 75 TUL. L. REV. 631, 658 (2001) (“Representative Jack Brooks
(Texas), perhaps the harshest critic of the proposed legislation, expressed doubts
that granting an exclusive license to industry after paying to develop a patentable
invention was an incentive to commercialize.”).

R

R

\\jciprod01\productn\C\CRN\102-2\CRN201.txt

2017]

unknown

Seq: 19

17-JAN-17

A MARKET TEST FOR BAYH–DOLE PATENTS

10:50

289

might not realize their potentially beneficial public use.”78
Stanford’s Office of Technology Licensing—one of the most effective university technology transfer offices by many metrics—
argues that “licensing often is the only way a new invention will
ever become a product.”79 The Association of University Technology Managers (AUTM) argues that “few [university] inventions were commercialized” before Bayh–Dole (though it might
be more accurate to say that few university inventions were
patented and licensed in an easily quantifiable way).80 AUTM
has collected over 500 inspiring stories of successful licensing
of university patents for its Better World Project, ranging from a
device that enables severely disabled people to express themselves by controlling a computer screen with eye movements
(based on research at Boston College) to a method of growing
trees three times faster and with less water by starting their
growth in a laboratory (from Washington State University).81
We do not dispute that exclusive patent rights are needed
for efficient commercialization of at least some—and perhaps
most—university inventions. As explained in the Introduction,
this theory is particularly compelling in the context of
pharmaceuticals that require expensive clinical trials to bring
to market but that are comparatively cheap to replicate.82 And
there may be some cases in which the inventor’s tacit knowledge is indispensable for technology transfer.83 But commercialization theory cannot justify patents for products that firms
78
Bd. of Trs. of Leland Stanford Jr. Univ. v. Roche Molecular Sys., 563 U.S.
776, 797 (2011) (Breyer, J., dissenting); see also id. at 782 (majority opinion) (“In
1980, Congress passed the Bayh–Dole Act to ‘promote the utilization of inventions
arising from federally supported research’ . . . .” (quoting 35 U.S.C. § 200 (2012)));
In re Roche Molecular Sys., Inc., 516 F.3d 1003, 1008 (Fed. Cir. 2008) (“The
purpose of the Bayh–Dole Act is as an incentive, not a bar, to university-industry
collaboration and commercial development through licensing . . . .”).
79
Wiesendanger, supra note 66.
80
The Bayh–Dole Act: It’s Working, ASS’N OF UNIV. TECH. MANAGERS, http://
www.autm.net/AUTMMain/media/Advocacy/Documents/BayhDoleTalking
PointsFINAL.pdf [https://perma.cc/5BD2-EPC5].
81
Featured Stories, ASS’N OF UNIV. TECH. MANAGERS BETTER WORLD PROJECT,
http://www.betterworldproject.org/featured-stories [https://perma.cc/T4K544MX]. Many of these stories focus on the startups generated by university licenses, perhaps for political economy reasons. While related to commercialization theory, the startup-generating function of Bayh–Dole patents could be viewed
as a normative theory of its own. See Rai et al., supra note 12, at 1555 (“Even if
patenting and exclusive licensing of software do not facilitate commercialization
per se, one might argue that exclusive licenses to university patents are useful for
software start-ups, and promoting such start-ups is a socially valuable goal.”).
We think this issue, like the other justifications for Bayh–Dole we discuss, deserves more empirical attention.
82
See supra notes 30-31 and accompanying text.
83
See supra note 74 and accompanying text.
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are eager to develop without exclusivity, such as when firms
developed a product under inexpensive nonexclusive licenses
or without awareness of the patent at all. Robin Feldman and
Mark Lemley have shown that ex post licensing demands are
unlikely to generate technology transfer.84 And as Mark Lemley has noted, “the validity of commercialization theory depends a great deal on the industry in question and the
particular nature of the technology.”85 The problem is that no
one has figured out how many other inventions look like
pharmaceuticals. We return to this problem in subpart II.B,
but first, the remainder of this subpart describes a few alternative justifications that have been put forth for university
patents.
3. Disclosure, Transactions, and Signals
In addition to providing incentives to invent and commercialize inventions, scholars have noted that patents may facilitate disclosure and exchange of information about new
technologies.86 Disclosure of technical information is often
cited by Supreme Court as one of the key reasons we have
patents.87 As one of us has explained, scholars have often
underestimated the benefit provided by patent disclosures, but
these benefits cannot justify the patent system.88 A different
strand of disclosure literature emphasizes that patents allow
84
See Robin Feldman & Mark A. Lemley, Do Patent Licensing Demands Mean
Innovation?, 101 IOWA L. REV. 137, 174–76 (2015).
85
Lemley, Are Universities Patent Trolls?, supra note 9, at 622–23.
86
For a review of these more recent justifications for the patent system, see
generally Stephen Yelderman, Coordination-Focused Patent Policy, 96 B.U. L. REV.
(forthcoming 2016), http://ssrn.com/abstract=2481025 [https://perma.cc/
9S8E-MJTF].
87
See, e.g., Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S.
722, 736 (2002) (“[E]xclusive patent rights are given in exchange for disclosing the
invention to the public.”); J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred Int’l, Inc., 534
U.S. 124, 142 (2001) (“The disclosure required by the Patent Act is ‘the quid pro
quo of the right to exclude.’” (quoting Kewanee Oil Co. v. Bicron Corp., 416 U.S.
470, 484 (1974))); Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141,
151 (1989) (“In consideration of [the invention’s] disclosure and the consequent
benefit to the community, the patent is granted.”); Kewanee Oil, 416 U.S. at 481
(stating that additions from patent disclosures “to the general store of knowledge
are of such importance . . . that the Federal Government is willing to pay the high
price of 17 years of exclusive use for its disclosure”).
88
See Lisa Larrimore Ouellette, Do Patents Disclose Useful Information?, 25
HARV. J.L. & TECH. 531, 545 (2012) [hereinafter Ouellette, Do Patents Disclose
Useful Information?]; see also Machlup Report, supra note 49, at 33 (noting the
“poor reception in economic literature” for disclosure theory); Alan Devlin, The
Misunderstood Function of Disclosure in Patent Law, 23 HARV. J.L. & TECH. 401,
403 (2010) (“As a primary function of [the patent] system, disclosure is both
ineffective and potentially poisonous to larger social goals . . . .”).

R

R

\\jciprod01\productn\C\CRN\102-2\CRN201.txt

2017]

unknown

Seq: 21

17-JAN-17

A MARKET TEST FOR BAYH–DOLE PATENTS

10:50

291

disclosure through channels outside the patent specification
by solving Arrow’s information paradox—though this theory
too faces empirical and theoretical challenges.89 Yet another
disclosure argument is that patents act as signals that allow
firms to credibly convey information to third parties—though it
is unclear that patent laws do better than securities laws in
fulfilling this role.90
Whatever weight these arguments pull in justifying the
patent system in general, we think they have little force for
federally funded inventions. Researchers already have strong
incentives to disclose their results through peer-reviewed publications.91 The grants themselves often require disclosure of
the research results,92 and in a world without Bayh–Dole,
grantees could be required to make patent-like disclosure of
their findings. The Bayh–Dole regime may even depress or delay academic disclosure if scientists worry that non-patent disclosures may limit their later ability to patent.93
Publications and grants also act as strong signals to third
parties about researchers’ and universities’ innovativeness. It
may be, as Dan Burk suggests, that the signaling value of
patents helps descriptively explain why universities frequently
engage in patenting activities that seem economically irrational,94 but this certainly does not justify the costs of university patenting.
4. Revenue for University Research
An explanation that might make more sense in the university context—and that is distinct from justifications for the
patent system in general—is that the revenues from licensing
university patents can be used to provide additional funding for
other scientific research. The Bayh–Dole Act specifies that “the
balance of any royalties or income earned by the contractor
with respect to subject inventions, after payment of expenses
(including payments to inventors) incidental to the administra89
For a summary of this literature, see Hemel & Ouellette, Beyond the Patents–Prizes Debate, supra note 32, at 357.
90
See id. at 358.
91
See Rai, supra note 24, at 119 (“Well before Bayh–Dole allowed universities
to seek patent rights on their inventions, American research universities were
publishing pioneering research.”).
92
See supra note 53 and accompanying text.
93
See Margo A. Bagley, Academic Discourse and Proprietary Rights: Putting
Patents in Their Proper Place, 47 B.C. L. REV. 217, 240–41 (2006).
94
Dan L. Burk, On the Sociology of Patenting, 101 MINN. L. REV. (forthcoming
2016) (manuscript at 4–5), http://ssrn.com/abstract=2740947 [https://
perma.cc/C78J-5L6S].
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tion of subject inventions, be utilized for the support of scientific research or education.”95 Stanford’s technology transfer
office lists revenue as its first argument in favor licensing university patents:
[W]hile the federal government has traditionally been the major sponsor of basic research conducted in universities, the
current trend is to limit such funding. Universities thus are
faced with the need to develop alternate sources of funding or
to curtail their research activities. Licensing income can be a
critical source of much-needed unrestricted funding.96

A former technology-transfer officer described revenue generation as “the unstated aim” of university patent licensing.97 Peter Detkin, whose firm Intellectual Ventures has licensed
“thousands of university patents” and paid “about US$110 million to universities and government researchers” in the past ten
years, argues that these licenses allow universities “to recoup
their research dollars and reward their inventors.”98
For some, this argument is less easily dismissed than the
idea that Bayh–Dole patents provide significant ex ante incentives to individual researchers or disclosure benefits. Academics often find it hard to oppose a new source of university
research support in an era of declining (and often risk-averse99)
federal funding. Revenue from patent licensing is an unrestricted source that some universities may be able to invest
even more wisely than federal grant agencies. This revenue
gain may be an underappreciated benefit of the Bayh–Dole Act.
But we are not convinced that this benefit can bear the weight
of independently justifying university patents that are unnecessary for commercialization.
First, it is worth bearing in mind that this revenue stream
is not free; as one of us has previously explained, the higher
price of patented inventions is equivalent to a “shadow tax”
that is transferred from the consumers of those inventions to
the rightsholders without passing through the federal
95

35 U.S.C. § 202(c)(7)(C) (2012).
Wiesendanger, supra note 66.
97
Ledford, Universities Struggle to Make Patents Pay, supra note 7, at 471
(quoting Melba Kurman, “a former technology-transfer officer at Cornell
University”).
98
Peter Detkin, Correspondence, Patents: Universities Are Right to Partner,
502 NATURE 448 (2013).
99
For a clever empirical study suggesting that more federal agencies should
adopt a riskier, long-term strategy in awarding grants, see Pierre Azoulay et al.,
Incentives and Creativity: Evidence from the Academic Life Sciences, 42 RAND J.
ECON. 527 (2011).
96
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budget.100 But from the public’s perspective, there is little difference between the patent shadow tax and an actual sales tax,
so this on-budget/off-budget distinction ought not matter for
innovation policy design.101 Furthermore, funding research
through broad-based taxation rather than a concentrated tax
on users of the resulting invention is generally more efficient,
so it is hard to make the case for shifting funding of university
research away from tax-funded grants and toward patent
rents.102
University technology transfer also appears to be a highly
inefficient way to raise revenue for university research. In fact,
most universities do not appear to generate revenue at all: one
report estimated that of the 155 universities reporting to the
AUTM survey, 130 did not generate enough licensing revenue
in 2012 to cover their expenses that year.103 As many as 95%
of university patents are unlicensed,104 suggesting that technology transfer offices are ineffective at choosing which inventions to patent or that they are patenting for non-monetary
reasons, such as the signaling goal discussed above. Outgoing
AUTM President Fred Reinhart recently stated, “We don’t file
patent applications to get rich. We don’t file patent applications for any reason other than [that] our licensees want . . . a
protected time period to justify the investment they’re going to
make in creating a product or a service.”105 Revenue might be
increased through the patent litigation strategies noted in the
Introduction,106 but litigation seems like an even more ineffi100
Hemel & Ouellette, Beyond the Patents–Prizes Debate, supra note 32, at
312–13, 371–73.
101
Id. at 371.
102
See Gene M. Grossman & Edwin L.-C. Lai, International Protection of Intellectual Property, 94 AM. ECON. REV. 1635, 1640 (2004); Amy Kapczynski, Intellectual Property’s Leviathan, LAW & CONTEMP. PROBS., Fall 2014, at 131, 133.
103
WALTER D. VALDIVIA, UNIVERSITY START-UPS: CRITICAL FOR IMPROVING TECHNOLOGY TRANSFER 9 (Ctr. for Tech. Innovation at Brookings, 2013); see also Ashley J.
Stevens, Do Most Academic Institutions Lose Money on Technology Transfer?,
Presentation at ‘Annual Meeting of the Tech. Transfer Soc’y (2005) at 31, http://
sites.kauffman.org/pdf/tt/Stevens_Ashley.pdf [https://perma.cc/G9Z5-HVCF]
(reporting that, from 1992–2004 just over half of university technology transfer
offices had a “[p]ositive [f]inancial [c]ontribution”).
104
Ledford, Universities Struggle to Make Patents Pay, supra note 7, at 472
(“Joy Goswami, assistant director of the technology-transfer office at the University of Delaware in Newark, estimates that only about 5% of patents are licensed
at most universities. The rest are a drain on office resources, he adds, because of
required maintenance and legal fees.”).
105
Gene Quinn, Exit Interview: A Conversation with Outgoing AUTM President
Fred Reinhart, IPWATCHDOG (Feb. 14, 2016), http://www.ipwatchdog.com/2016/
02/14/autm-president-fred-reinhart/id=66075 [https://perma.cc/2J7A-RBDV].
106
See supra notes 7–12 and accompanying text.
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cient method of funding university research. As Reinhart
stated on behalf of AUTM, “We don’t like litigation. There’s
nothing great about it. We’re not set up to engage in it. It’s
expensive. It’s time-consuming, distracting and it doesn’t look
good for anybody to be involved with litigation . . . .”107
These sobering statistics do not mean that the revenuerecycling aspect of Bayh–Dole could not become an important
benefit. According to AUTM statistics, the gross licensing income reported by U.S. universities and nonprofit research institutes has been increasing faster than their legal fees.108 But
if revenue generation is the best justification for many
Bayh–Dole patents, then we think this demands a serious public debate about whether this benefit is worth the significant
costs, whether Bayh–Dole could be restructured to make this
revenue-generation function more efficient, and whether there
are better ways to achieve this goal.109
5. International Considerations
In a separate article, one of us, along with Daniel Hemel,
describes an overlooked benefit of Bayh–Dole: by allowing the
United States to internalize some of its grant spending,
Bayh–Dole may encourage more efficient levels of grant spending in the first place.110 Here, we review this new “internalization theory” and address how it might affect our proposal.
A rational U.S. policymaker should invest in direct R&D
spending on a given topic up to the point that the marginal
benefits to the United States exceed the marginal cost. But the
results of this R&D spending often have benefits for citizens of
other countries, and unless these foreign benefits are taken
107
Quinn, supra note 105. Additionally, even if some universities are successful in monetizing their patent portfolios, it is far from clear that this revenue
stream is correlated with the amount that the university’s research should be
subsidized going forward.
108
See Hemel & Ouellette, Bayh–Dole Beyond Borders, supra note 48 (manuscript at 15 fig.1) (graphing data from Statistics Access for Technology Transfer
(STATT) Database, supra note 16).
109
See, e.g., Jacob H. Rooksby, Innovation and Litigation: Tensions Between
Universities and Patents and How to Fix Them, 15 YALE J.L. & TECH. 312, 312
(2013) (proposing “allow[ing] universities to enjoy the revenue-generation aspect
of patent ownership while freeing them from the legal compulsion to participate as
co-plaintiffs with their exclusive licensees in enforcement actions”).
110
Hemel & Ouellette, Bayh–Dole Beyond Borders, supra note 48; see also
Daniel J. Hemel & Lisa Larrimore Ouellette, Knowledge Goods and Nation-States,
101 MINN. L. REV. (forthcoming 2016), http://ssrn.com/abstract=2745632
[https://perma.cc/3EPW-Y4BY] [hereinafter Hemel & Ouellette, Knowledge
Goods and Nation-States] (noting the implications of this benefit for debates over
IP treaties).
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into account, the rational U.S. investment level will be less
than the globally optimal amount. This hypothesis of underinvestment in knowledge production in the absence of global
coordination is the conventional economic justification for international patent treaties.111 (Most importantly, almost every
country—and every economically significant country—is a
member of the World Trade Organization and thus must comply with the twenty-year patent requirement of the Agreement
on Trade-Related Aspects of Intellectual Property Rights, or
TRIPS.112) Under this account of international IP law, as explained by the late innovation economist Suzanne Scotchmer,
“harmonized intellectual property protections allow countries
to recoup some of the benefits they confer on foreign consumers,” and thus “there may be too little public sponsorship and
too much intellectual property” at the domestic level.113
Those harmonized intellectual property protections, however, may actually encourage IP alternatives like public
sponsorship:
[I]t is worth noting that the common concern that allowing IP
protection on publicly supported works requires U.S. taxpayers to “pay twice” overlooks the point that not allowing IP
protection permits non-U.S. consumers to avoid paying at all.
When combined with international IP treaties, Bayh-Dole regimes may encourage states to increase direct public funding
for research, alleviating Scotchmer’s concern that IP treaties
at the international level will cause “too little public sponsorship” at the domestic level.114

Unless government grantees can obtain patent protection for
inventions generated by government-funded research, the
111
See, e.g., Suzanne Scotchmer, The Political Economy of Intellectual Property
Treaties, 20 J.L. ECON. & ORG. 415, 420 (2004) (explaining that absent global
coordination, “both public sponsors and private investors have deficient incentives to invest, relative to what is efficient” due to “uncompensated externalities
abroad”).
112
See Agreement on Trade-Related Aspects of Intellectual Property Rights
arts. 27, 33, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade
Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197 (requiring patents “in
all fields of technology” with protection lasting at least twenty years from filing);
Members and Observers of the WTO, WORLD TRADE ORG., https://www.wto.org/
english/thewto_e/countries_e/org6_map_e.htm [https://perma.cc/E7ZH-DYZT]
(last updated July 29, 2016) (showing the 164 members of the WTO on a map);
Accession in Perspective, WORLD TRADE ORG., https://www.wto.org/english/
thewto_e/acc_e?/cbt_course_e/c1s1p1_e.htm [https://perma.cc/9LZ5-NY32]
(noting that WTO members represent over 96% of global GDP and trade).
113
Scotchmer, supra note 111, at 415, 436.
114
Hemel & Ouellette, Knowledge Goods and Nation-States, supra note 110;
see Hemel & Ouellette, Bayh–Dole Beyond Borders, supra note 48 (describing this
internalization theory of Bayh–Dole in more detail).
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United States would have no practical way of internalizing the
positive externalities conferred on consumers in other countries who use products produced through U.S. taxpayer-financed research. By allowing the United States to internalize
benefits that federally funded inventions bring to consumers
abroad, the Bayh–Dole Act plausibly leads U.S. lawmakers to
invest more in public research funding in the first place.115
We naturally have no quibble with this account, though it
remains untested, and this benefit may be outweighed by the
costs of patenting in many cases.116 Here, we simply note that
if this novel account is in fact a significant justification for
many Bayh–Dole patents—in particular, those for which exclusivity is unnecessary for commercialization—then it would require a change in Bayh–Dole implementation. The optimum
Bayh–Dole regime might then involve more significant patenting abroad and use of our market test proposal only for domestic users of university inventions. We thus will cabin this
consideration for now. But if further research provides additional support for the theory that payments from foreign consumers increase the willingness of federal policymakers to
provide more efficient levels of direct R&D support in the first
place, then it may be worth limiting our proposal to the domestic sphere.117
6. Copyleft-Style Patent Licensing
A final potential benefit of Bayh–Dole patents is an extension of the point that exclusivity is sometimes unnecessary for
commercialization. In some cases, a technology might develop
most efficiently not only without constraints on the initial basic
inventions that originated from federally funded university research, but also without subsequent patenting by the private
firms that use the technology. Universities can help with this
goal by patenting foundational technologies and then freely
licensing them under the condition that licensees use the same
open license terms with related innovations. This approach
115
Hemel & Ouellette, Bayh–Dole Beyond Borders, supra note 48 (discussing
possible mechanisms through which this might occur).
116
See id. This is a specific example of a more general point about IP laws
made by Brett Frischmann and Mark Lemley: “even where internalizing externalities increases incentives to invest, the social costs of relying on property rights to
do so still may exceed the benefits.” Brett M. Frischmann & Mark A. Lemley,
Spillovers, 107 COLUM. L. REV. 257, 258 (2007).
117
Note that the implementing regulations for the Bayh–Dole Act allow agencies to take title to the invention in any country in which a university does not
pursue protection. 37 C.F.R. § 401.14(d)(3) (2015).
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was pioneered in the software context with copyright licenses,
where it came to be known as “copyleft.”118
The effectiveness of such a strategy is limited by important
differences between copyrights and patents. Most notably,
copyright affixes automatically and costlessly, whereas patents
are expensive and time-consuming to obtain.119 As David
Grewal has described, these difficulties caused synthetic biology pioneers to abandon their initial plans to create an affirmative copyleft-style licensing commitment for basic synthetic
biology building blocks in favor of a strategy of simply dedicating these inventions to the public domain.120
Universities may have more success in using their upstream patents to demand downstream licensing commitments
related to access in low-income countries. As one of us has
demonstrated, the majority of FDA-approved pharmaceuticals
with university patents also have a follow-on patent with no
university assignee.121 A university that develops an initial
drug candidate and then licenses it to a pharmaceutical company for clinical trials could require that no follow-on patents
related to that drug be filed in certain countries.122 The same
approach could also be used in non-pharmaceutical areas,
such as green technologies.123
The ability to engage in these copyleft-style strategies may
be an important benefit of some university patents.124 But
note that unlike the features of university patents described
above, this benefit depends on limiting the constraints on production that patents impose. It is thus not an argument
against using our market test. Rather, by demonstrating when
exclusivity is unnecessary for commercialization, our market
118

See YOCHAI BENKLER, THE WEALTH OF NETWORKS 65 (2006).
See Lexmark Int’l v. Impression Prods., 816 F.3d 721, 761 (Fed. Cir. 2016)
(en banc) (“Patents involve costly government-approval processes . . . . Copyrights
are different. They generally spring into being without any government
approval . . . .”).
120
David Singh Grewal, Before Peer Production: Infrastructure Gaps and the
Architecture of Openness in Synthetic Biology, 19 STAN. TECH. L. REV. (forthcoming
2017) (manuscript at 22–37).
121
Ouellette, How Many Patents Does It Take To Make a Drug?, supra note 30,
at 319.
122
See id. at 322; see also infra notes 171–172 and accompanying text
(describing the success universities have had in promoting access to their technologies in developing countries).
123
See Ouellette, Addressing the Green Patent Global Deadlock, supra note 6.
124
See generally Peter Lee, Toward a Distributive Commons in Patent Law,
2009 WIS. L. REV. 917 (describing the role of noncommercial, humanitarian norms
in university patenting).
119
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test may illuminate those areas of technology for which
copyleft-style patent licenses might be most fruitful.
B. When Is an Exclusive Right Necessary for
Commercialization?
As explained in subpart I.A, while there are numerous theories of Bayh–Dole patents that deserve more attention, the
only case in which there is currently convincing evidence that
the social costs of patents are worth bearing is when an exclusive right is necessary for commercialization. Yet it is unclear
when that condition is satisfied. Bayh–Dole has certainly increased the number of quantifiable licenses of university patents, such as those detailed in AUTM’s Better World Project.125
But how many of these inventions would have been quickly
adopted anyway even if they hadn’t been patented? Were the
ideas of controlling a computer screen with eye movements and
growing trees faster in laboratories so valuable that firms
would have marketed these inventions without patent protection, or were the markets for these ideas so risky and uncertain
that no firm would have entered without a patent? In other
words, are these inventions more like traditional pharmaceuticals or more like the recombinant DNA techniques covered by
the Cohen–Boyer patents?
It is impossible to observe the counterfactual parallel universe in which these inventions were not patented, so estimating the causal effect of exclusive patent rights in any given
historical case is challenging. But we can at least conclude
with confidence that exclusive rights are not always needed:
the fact that universities have often licensed inventions on a
nonexclusive basis is evidence that an exclusive patent right
was not necessary. In fact, over sixty percent of the thousands
of licenses reported each year on a survey of technology transfer offices are nonexclusive.126 As explained above, these licenses (and the underlying patents) are likely not welfare
enhancing.127
125

R

126

R

See supra note 81.
See supra note 16. As noted there, we do not know what proportion of
Bayh–Dole revenue these nonexclusive licenses generate.
127
Of course, it is possible that the fees for these nonexclusive licenses were
set high enough to restrict quantity to the monopoly level, in which case they are
effectively equivalent to exclusive licenses. But it seems unlikely to us that universities and their licensees would regularly choose such a structure over an
actual exclusive license.
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The high-profile litigations mentioned above help illustrate
these critiques.128 The inventions at issue were funded by taxpayers and published in scientific journals, so it is difficult to
argue that patents were needed to incentivize these university
scientists to create and disclose these inventions. Most of the
funding for the high-tech patents asserted by Carnegie Mellon,129 Wisconsin,130 and Boston University131 was provided by
the National Science Foundation (NSF). Boston University
sought patent protection in Japan and the European Patent
Office,132 so there may be some internalization benefit from
these foreign patents, but Wisconsin and Carnegie Mellon appear to have only patented their inventions domestically.133
And given that the universities licensed these inventions
128
Supra notes 9–12 and accompanying text. For additional examples of universities using patents in ways that seem contrary to the public-spirited goal of
commercialization, see Lee, Patents and the University, supra note 21.
129
U.S. Patent No. 6,201,839 col. 1 l. 13–14 (filed Apr. 3, 1998); U.S. Patent
No. 6,438,180 col. 1 l. 13–14 (filed Mar. 1, 1999); see Carnegie Mellon Univ. v.
Marvell Tech. Grp., 807 F.3d 1283, 1288–89 (Fed. Cir. 2015) (listing patents);
Aleksandar Kavcic & José M.F. Moura, Correlation-Sensitive Adaptive Sequence
Detection, 34 IEEE TRANSACTIONS ON MAGNETICS 763, 763 (1998) (noting support
from the same NSF grant listed in the patents); Aleksandar Kavcic & José M. F.
Moura, Matrices with Banded Inverses: Inversion Algorithms and Factorization of
Gauss–Markov Processes, 46 IEEE TRANSACTIONS ON INFO. THEORY 1495, 1495
(2000) (showing the same); Aleksandar Kavcic & José M. F. Moura, The Viterbi
Algorithm and Markov Noise Memory, 46 IEEE TRANSACTIONS ON INFO. THEORY 291,
291 (2000) (showing the same).
130
U.S. Patent No. 5,781,752 col. 1 l. 5–9 (filed Dec. 26, 1996) (also noting
support from the Army (ARPA) and the Navy (ONR)); see Wisconsin Alumni Research Found. v. Apple, Inc., No. 14-CV-062-WCC, 2015 WL 5009944, at *1 (W.D.
Wis. Aug. 20, 2015) (listing patent); Andreas Moshovos et al., Dynamic Speculation
and Synchronization of Data Dependences, PROC. 24TH ANN. INT’L SYMP. ON COMPUTER ARCHITECTURE, May 1997, at 181 (noting support from the same grants listed
in the patent).
131
See U.S. Patent No. 5,686,738 col. 1 l. 9–10 (filed Jan. 13, 1995) (claiming
priority to an application filed Mar. 18, 1991); T. Lei et al., Epitaxial Growth of Zinc
Blende and Wurtzitic Gallium Nitride Thin Films on (001) Silicon, 59 APPLIED PHYSICS
LETTERS 944, 946 (1991) (noting NSF support for the invention described in the
patent); see also Tim Stoddard, Green Light on Blue Light: Blue Light Technology
Remains BU’s Intellectual Property, B.U. BRIDGE (Dec. 13, 2002), https://
www.bu.edu/bridge/archive/2002/12-13/bluelight.htm [https://perma.cc/
NTR2-WEV6] (explaining why B.U. has patent rights to the blue LED based on this
1991 publication, even though another scientist, Shuji Nakamura, typically receives scientific credit—as he did in receiving the 2014 Nobel Prize in Physics).
132
See Highly Insulating Monocrystalline Gallium Nitride Thin Films, GOOGLE
PATENTS, https://patents.google.com/patent/US5686738A [https://perma.cc/
96EE-ZN3U] (containing links under “[a]lso published as” to parallel patents
granted in Japan and the European Union).
133
See Advanced Search, ESPACENET, http://worldwide.espacenet.com/advancedSearch [https://perma.cc/8ANG-4VEA] (search “Publication number” for
“US6201839” or “US5781752”; click the patent title; then click “INPADOC patent
family” to see that there are no foreign patents in the patent family).
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nonexclusively and that the firms they sued had commercialized the inventions without exclusivity, it is difficult to argue
that these inventions would not have been brought to practical
application if they had been in the public domain.
Our conclusion that federal grant recipients should seek
patents only when exclusive rights are necessary for commercialization should be unsurprising to those who have closely
followed the Bayh–Dole debates. Economic and legal scholars
concur on this point.134 The NIH—one of the largest federal
grant agencies—promulgated regulations instructing grant recipients that biomedical research tools and genomic inventions
should be patented and exclusively licensed only when necessary for commercialization.135 (These regulations are not binding and are typically not followed, though they may have
hortatory value.136) And over one hundred universities themselves have endorsed a (also non-binding) statement of licensing principles stating that universities “should strive to grant
just those rights necessary to encourage development of the
technology.”137
But to our knowledge, no one has yet proposed any systematic way to determine whether a given invention needs exclusive patents. The underlying problem is asymmetric
information about the costs of commercialization. If policymakers had full information about these commercialization
costs, there would be better policy tools than patents to ad-

134
See, e.g., Arti K. Rai & Rebecca S. Eisenberg, Bayh–Dole Reform and the
Progress of Biomedicine, LAW & CONTEMP. PROBS. Winter/Spring 2003, at 289, 30001 (noting that nonexclusive licenses “impose[ ] a modest tax on product development” and function only “to generate revenue for the patent owner,” which is not a
goal of the Bayh–Dole Act); Bhaven N. Sampat, Patenting and US Academic Research in the 20th Century: The World Before and After Bayh–Dole, 35 RES. POL’Y
772, 786 (2006) (“[F]rom a social welfare perspective . . . we would want universities to issue exclusive licenses on patented inventions only when non-exclusive
licensing fails to promote use or commercialization.”).
135
Best Practices for the Licensing of Genomic Inventions: Final Notice, 70
Fed. Reg. 18413 (Apr. 11, 2005); Principles and Guidelines for Recipients of NIH
Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice, 64 Fed. Reg. 72090 (Dec. 23, 1999).
136
Rai & Eisenberg, supra note 134, at 293–94.
137
CAL. INST. OF TECH. ET AL., IN THE PUBLIC INTEREST: NINE POINTS TO CONSIDER IN
LICENSING UNIVERSITY TECHNOLOGY 2 (2007), https://otl.stanford.edu/documents/
whitepaper-10.pdf [https://perma.cc/PX34-4BLW]. For a list of the over one
hundred institutions that have signed the Nine Points, see Nine Points To Consider, ASS’N. OF UNIV. TECH. MANAGERS, http://www.autm.net/advocacy-topics/
government-issues/principles-and-guidelines/nine-points-to-consider-when-li
censing-university [https://perma.cc/D2PR-BZTL].
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dress this market failure.138 As described in section III.A.2, the
Bayh–Dole Act has a built-in tool to address some of the social
costs of university patenting—march-in rights—but these have
so far proved ineffective.139 What is needed is a mechanism to
cause private parties to reveal their commercialization costs—
and we think that the market test we describe in Part II can
satisfy this need.
II
THE SOLUTION: A MARKET TEST OF EXCLUSIVITY FOR
BAYH–DOLE PATENTS
In Part I, we argued that Bayh–Dole patents are currently
justified only to the extent needed for commercialization. Here,
we describe our proposal for a market test to determine
whether exclusive rights are in fact needed for any given invention. In subpart II.A, we explain the basic idea behind the
market test: by seeing whether firms will commit to commercializing federally funded inventions for less than the full exclusive patent term—such as under a free nonexclusive license—
universities can determine whether exclusivity is needed in a
given case.
In subpart II.B, we introduce a formal model and demonstrate that in cases when no firm will commit to a commercialization under a free nonexclusive license, the university can still
do better (from a social welfare perspective) than granting an
exclusive license for the full patent term. The university can
offer the inventions under an auction, but not a traditional
auction to see which firm would pay the most for the license—
rather, the metric of auction competition would be the exclusivity received by the firm.140 Our proposal is focused on only the
minority of Bayh–Dole patents for which there are eager licen138
See Hemel & Ouellette, Beyond the Patents–Prizes Debate, supra note 32,
at 327–33 (discussing information asymmetries and government-set versus market-set innovation incentives).
139
See 42 U.S.C. § 203 (2012).
140
The possibility of changing the metric of auction competition to enhance
social welfare has a long tradition. See, e.g., Barry E. Adler & Ian Ayres, A Dilution
Mechanism for Valuing Corporations in Bankruptcy, 111 YALE L.J. 83, 83 (2001);
Ian Ayres & Joel Waldfogel, A Market Test for Race Discrimination in Bail Setting,
46 STAN. L. REV. 987, 1037–38 (1994); Ian Ayres & Barry Nalebuff, A Market Test
for Credit Cards, Forbes (June 25, 2009, 10:00 PM), http://www.forbes.com/
forbes/2009/0713/opinions-market-credit-cards-why-not.html [http://perma.
cc/E7UB-ESQF]. In the patent context, Michael Abramowicz has proposed using
an exclusivity duration auction to encourage the commercialization of orphan
drugs. Michael Abramowicz, Orphan Business Models: Toward a New Form of
Intellectual Property, 124 HARV. L. REV. 1362, 1396–97 (2011).
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sees,141 and it thus would not change anything for patents that
are currently unlicensed (or for which there is only one willing
licensee), such as those involved in Penn State’s recent auction
of its unlicensed patents.142
One possible metric for our auction is years of exclusivity,
though one can produce the same incentive by granting weaker
rights over more years than stronger rights over fewer years, as
one of us has illustrated.143 We thus show that deadweight
loss is reduced by auctioning based on who will charge the
smallest markup on the end product. We note, however, that
this metric does not work well whenever there are many patents per product. We also consider the possibility of defensive
commercialization by firms that want to avoid being the victim
of the patent, and we reach the surprising conclusion that this
kind of strategic bidding does not increase the cost to society.
A. Basic Structure of the Market Test
The basic idea underlying our proposal is that universities
(and other institutions covered by the Bayh–Dole regime)
should test the market to determine how federally funded inventions can be commercialized with the least cost to society.
As we have explained, exclusivity is justified only when needed
for commercialization, and nonexclusive licenses are generally
against the public interest: inventions that firms are willing to
commercialize without exclusivity should not have been patented at all.144
Under the simplest version of our market test, before
granting an exclusive patent license, universities would be required to offer an invention under a nonexclusive license for a
nominal fee. Alternatively, as a way to reduce the administrative costs of the market test and to ensure that the majority of
university patents are unaffected, firms willing to commercialize without exclusivity should have the opportunity to object to
a university’s exclusive patent license within some
141
As noted above, as many as 95% of university patents are unlicensed. See
supra note 104 and accompanying text. We are focused instead on the patents
that are in the highest demand and which thus create the highest deadweight
loss.
142
See Daniel R. Cahoy et al., The Role of Auctions in University Intellectual
Property Transactions, 54 DUQUESNE L. REV. 53, 54–55 (2016).
143
Ian Ayres & Paul Klemperer, Limiting Patentees’ Market Power Without
Reducing Innovation Incentives: The Perverse Benefits of Uncertainty and NonInjunctive Remedies, 97 MICH. L. REV. 985, 1001–03 (1999).
144
See supra subpart I.A.
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timeframe.145 If a firm is willing to commit to commercializing
the invention without exclusivity (with contractual provisions
to ensure that the firm follows through on this commercialization commitment, discussed further in subpart II.C), then exclusivity is not warranted and the university would then be
required to continue to license to all and any subsequent licensees for free.146
Alternatively, universities could be prohibited from charging even for the initial nonexclusive license, which would create
a strong incentive against filing patents where exclusivity is
unlikely to be needed for commercialization. It seems impractical, however, to have universities bear the risk of a patent
turning out to be unnecessary, and there is value in having the
universities disclose inventions early, including to preclude
private firms from obtaining these unnecessary patents under
first-to-file rules. It thus likely would be preferable to allow
universities to charge a nominal fee for nonexclusive licenses
with a reasonable revenue cap to cover the costs of obtaining
and licensing the patent (plus the costs of obtaining other patents that never found a licensee).
But what if no firms will commit to commercialization for
the free (or cheap) nonexclusive license? Does that mean that
the university should grant an exclusive license for the full
patent term in order to ensure commercialization? In the next
section, we show that the answer is “no”: universities could be
required to use an auction to discover whether limited exclusivity was sufficient to induce commercialization. Of course, it
may still be the case that there is only one willing commercializer, such as when the inventor’s tacit knowledge is indispensable for commercialization.147 But our auction can be used to
145
This alternative might lead to the lowest administrative cost, given that our
auction likely would not change the status quo for the vast majority of university
patents. See supra note 141 and accompanying text.
146
We refer to “the invention” for simplicity, but a single disclosure may lead
to many claims spread across a large patent family, with applicability in numerous fields of use. See Sandra L. Shotwell, Field-of-Use Licensing, in 2 INTELLECTUAL
PROPERTY MANAGEMENT IN HEALTH AND AGRICULTURAL INNOVATION: A HANDBOOK OF BEST
PRACTICES 1113 (Anatole Krattiger et al. eds., 2007), http://www.iphandbook.org/
handbook/resources/Publications/links/ipHandbook%20Volume%202.pdf
[https://perma.cc/NFP9-RPS6]. In some cases, it may be appropriate to separately license different claims from the same family, or to separately license a
single claim in different fields of use. For example, a new protein product could be
licensed exclusively for development of a new therapeutic drug and nonexclusively for its use in other sectors. See id. at 1114.
147
Such patents may be invalid for lack of enablement, however. Cf. Ouellette,
Access to Bio-Knowledge, supra note 44, ¶¶ 106–13 (explaining why inventions
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distinguish these cases from those in which commercialization
is clearly possible at lower social cost.
B. Modeling Bayh–Dole Patent Exclusivity Auctions
Here, we analyze the probable outcome of a formal commercialization auction in which a bidder promises, if it wins the
auction, to commercialize an invention in return for limited
exclusivity rights. We abstract away from important questions
of enforcement and timing discussed below.148 Instead, we focus here on how an auction can simultaneously reveal (1)
whether granting exclusive patent rights is necessary and (2)
what is the minimum grant of exclusivity necessary to incentivize commercialization.
Our proposed auction is analogous to a procurement auction in which the government puts out for bid items or services
that it wishes to purchase and the seller with the lowest bid
wins. In our setting, the bidders are selling commercialization
services in exchange for limited exclusivity rights. For example, an auction in which bidders compete over the length of the
exclusivity period would be won by the bidder who is willing to
commercialize the invention for the fewest years of exclusive
rights.
Note that the purpose of this exclusivity auction is not to
identify the lowest bidder with the lowest commercialization
cost: whoever wins will have a Coasean incentive to contract
with the most efficient commercializer. Rather, the purpose is
to harness knowledge of the lowest-cost commercializer (which
may or may not reside with that party) in order to reduce the
deadweight-loss distortion caused by unnecessary exclusivity.
In many cases, the lowest-cost commercializer may be a startup that includes the university inventor, who will already have
tacit knowledge that complements the patent.149
A central result of game-theory, called the “revenue equivalence theorem,” establishes that a variety of auction mechanisms—including the English (ascending open outcry), Dutch
(descending open outcry), Vickrey (second-price sealed), and
first-price sealed auctions (where bidders account for the winner’s curse)—will generate the outcome where the bidder with
that cannot be produced from the patent document alone may be invalid under 35
U.S.C. § 112 (2012)).
148
See infra subpart III.B.
149
On the role of faculty inventors in technology transfer, see Peter Lee, Transcending the Tacit Dimension: Patents, Relationships, and Organizational Integration in Technology Transfer, 100 CALIF. L. REV. 1503, 1509, 1521–39 (2012).
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lowest reservation price will win the auction but in expectation
only pay the second lowest bidder’s value.150 For specificity
and to choose an auction procedure in which the bidders’ dominant strategy is simply to bid their reservation price, we assume that the commercialization auction is implemented with
a Vickrey auction in which the bidder bidding the least patent
protection wins, but receives the second-least protection bid.
Thus, if the auction is based on years of exclusivity, and firms
A, B, and C submit sealed bids stating that they would commercialize the invention in exchange for one, five, and ten years
of exclusivity, respectively, then firm A would win the auction
and would receive an exclusive license for five years—at which
point B and C could enter the market under a free nonexclusive
license.
1. Limiting the Deadweight Loss of Incentivizing
Commercialization
To analyze the probable outcome of such a commercialization auction, imagine that there are N bidders, each with costs
of commercialization C, independently drawn from the following distribution:
p = Probability that the ith bidder’s Ci is 0
(1 – p) = Probability that the ith bidder’s Ci is uniformly
distributed between $0 and $100.151
This distribution captures the spirit of our analysis because it assumes that there is some discrete probability that a
bidder can costlessly commercialize an invention, but also assumes that there is some probability that commercialization
costs are positive and vary within some range.
To begin, we assume that bidders are not potential users of
the invention and hence value any exclusive rights solely based
on the invention’s expected profits. For example, the invention
might be a medical device that is only of value to end users and
not as an input to any other industrial processes. We also
assume that the price discrimination in licensing is not costeffective so that the rightsholder is limited to a single price—as
150
R. Preston McAfee & John McMillan, Auctions and Bidding, 25 J. ECON.
LITERATURE 699, 710 (1987).
151
The assumption that the costs of commercialization are independently
distributed in effect assumes that this is a private valuation auction (in contrast
to common value auctions in which bidders’ knowledge of their own value draw
gives some additional information about other bidders’ values). See Peter
Cramton & Alan Schwartz, Using Auction Theory to Inform Takeover Regulation, 7
J.L. ECON. & ORG. 27, 28–29 (1991) (distinguishing between common value and
independent private value auctions).
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is standard in many monopoly markup models.152 We relax
these assumptions later.
As explained above, a bidder’s dominant strategy in our
auction is to bid her reserve price. With all bidders adopting
this strategy, the bidder with the lowest reserve price will win
the auction but be paid the second lowest bid. A non-consuming bidder’s reserve price will be (epsilon above) the amount
that produces expected profits equaling that bidder’s cost of
commercialization, Ci.
The expected outcome of any auction will thus turn on the
second lowest commercialization cost among the bidders. Using ordered statistics,153 the expected commercialization cost
of this pivotal bidder for a variety of possible numbers of bidders (N) and probabilities (p) of null commercialization costs is
provided in Table 1:
TABLE 1. EXPECTED SECOND-LOWEST COMMERCIALIZATION COST
FOR N BIDDERS WITH P PROBABILITY OF NULL
COMMERCIALIZATION COSTS.
p
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%

2
$60.00
$53.33
$46.67
$40.00
$33.33
$26.67
$20.00
$13.33
$6.67
$0.00

3
$42.53
$35.20
$28.18
$21.60
$15.63
$10.40
$6.08
$2.80
$0.73
$0.00

N
4
$32.08
$24.58
$17.84
$12.10
$7.50
$4.10
$1.84
$0.58
$0.08
$0.00

5
$25.15
$17.75
$11.60
$6.91
$3.65
$1.62
$0.55
$0.12
$0.01
$0.00

10
$9.86
$4.39
$1.61
$0.48
$0.11
$0.02
$0.00
$0.00
$0.00
$0.00

20
$2.44
$0.38
$0.04
$0.00
$0.00
$0.00
$0.00
$0.00
$0.00
$0.00

Thus, for example, if there are five bidders, and if each
bidder has a 30% chance of no commercialization costs (and a
70% chance of commercialization costs uniformly distributed
between $0 and $100), then the second lowest
commercialization cost among the bidders is expected to be
$11.60. As one would expect, the expected cost decreases as p
or N increases. The larger the number of bidders, the larger the
chance that two will have low draws and the larger p, the larger
152

See, e.g., Ayres & Klemperer, supra note 143, at 1013.
Expectations about “ordered statistics” can tell, inter alia, what is the
expected lowest or second-lowest (or third-lowest, etc.) value when a discrete
number of values are randomly drawn from some distribution. H. A. DAVID & H.
N. NAGARAJA, ORDER STATISTICS 9–22 (3d ed. 2003).
153
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the chance that at least two will have zero costs of
commercialization. Indeed, the probability that at least two
bidders will have null commercialization costs is provided in
Table 2:
TABLE 2. PROBABILITY OF TWO BIDDERS WITH NULL
COMMERCIALIZATION COSTS.

p

2

3

N
4

5

10

20

10%
20%
30%
40%
50%
60%
70%
80%
90%
100%

1.0%
4.0%
9.0%
16.0%
25.0%
36.0%
49.0%
64.0%
81.0%
100.0%

2.8%
10.4%
21.6%
35.2%
50.0%
64.8%
78.4%
89.6%
97.2%
100.0%

5.2%
18.1%
34.8%
52.5%
68.8%
82.1%
91.6%
97.3%
99.6%
100.0%

8.1%
26.3%
47.2%
66.3%
81.3%
91.3%
96.9%
99.3%
100.0%
100.0%

26.4%
62.4%
85.1%
95.4%
98.9%
99.8%
100.0%
100.0%
100.0%
100.0%

60.8%
93.1%
99.2%
99.9%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%

In our previous example, with five bidders and a 30% null
cost probability, there is a 47.2% chance that at least two of the
bidders will have zero commercialization costs. This possibility
is particularly relevant to our analysis because it suggests that
there are circumstances in which commercialization auctions
will produce outcomes with very little or no patent protection.
Auctions can spur efficiency by allowing rights and duties
to flow to the highest valuer.154 Commercialization auctions
might accordingly enhance efficiency by allowing the lowest
cost commercializer to win the right to commercialize. However,
we do not emphasize this benefit in our analysis because
university patentees already have incentives to find low-cost
commercializers. We observe universities co-venturing with
startups and established firms that are better suited to bring
inventions to the market. Indeed, nothing would stop
universities from holding their own procurement auction to
discover the least-cost commercializer. Rather, we focus on
how particular kinds of commercialization auctions can reduce
the deadweight loss of rightsholding relative to the current
monopoly pricing regime.
154

McAfee & McMillan, supra note 150, at 714.
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2. Competing over Duration or Revenue Caps
One approach to limiting patent power would be to have
the bidders—including the university—compete over the length
of the exclusive license. Bidders with lower Ci might be willing
to take on the costs of commercialization for substantially
fewer years of patent protection than the twenty years that
universities currently are granted. (The effective life of a patent
is of course twenty years minus the time in prosecution, but we
will refer to twenty-year patents for simplicity.155) If bidders
competed on license term by bidding the number of years ( Y )
of exclusive patent protection for which they would be willing to
take on the costs of commercialization, a bidder’s reservation
bid can be derived from the following equation:

Equation 1 sets the one-time commercialization cost Ci equal to
the annuitized monopoly profits per period (where Pm and Qm
are respectively the expected monopoly price and quantity, and
A(Y) = (1–(1+r)–Y)/r is the annuitization rate which is an increasing function of the number of years Y and a decreasing
function of the annual interest rate r).156 Bidders with lower Ci
would be willing to commercialize for fewer years of patent
protection, and bidders with no commercialization costs would,
if forced by other bidders in an auction, be willing to commercialize for a license of zero duration.
Alternatively, one could imagine an auction that limited
patent power, not by limiting the duration of the exclusive
rights, but by capping the revenue that could be earned in any
period.157 Under this regime, the rightsholder would gain an
exclusion right for twenty years but would be bidding on a
revenue amount lower than the monopoly revenue (Pm*Qm) that
it would be willing to receive in order to take on the commercialization obligation.158 (Such a structure would of course be
challenging if the invention represents only a minor component
155

35 U.S.C. § 154(a)(2) (2012).
We assume that other than the commercialization costs, there are no marginal costs to licensing the patent.
157
These are not the only possibilities. For example, Michael Abramowicz has
discussed how patents might be awarded through auctions to the party willing to
sell an invention for the lowest price. See Michael Abramowicz, The Uneasy Case
for Patent Races over Auctions, 60 STAN. L. REV. 803, 849–54 (2007).
158
This kind of auction might alternatively be structured so that bidders
would compete on the basis of price per unit or on licensing profits instead of
revenue. But administratively gross revenue is more readily observed for purposes of enforcement and produces identical results as price or profit auction in
model described in the appendix.
156
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of a product to which revenue can be tied, so there might be few
cases in which it is administratively feasible in practice.159) If
bidders competed on the maximum periodic revenue over an
invariant twenty-year rights period, a bidder’s reservation (revenue) bid (RB) would be derived by:

Equation 2 is analogous to Equation 1 except that it sets the
commercialization cost Ci equal to the annuitized revenue cap
per period. As with competition over the duration of exclusive
rights, revenue competition among bidders with no commercialization costs would produce commercialization with zero (or
epsilon) licensing revenue.
Either form of auction competition—over duration or over
revenue—has the potential of reducing the deadweight loss associated with the current Bayh–Dole patent regime. But it
turns out that the revenue cap auction produces less social
(deadweight) loss than the duration auction.
To see this with a simple numeric example,160 imagine that
the annual interest rate is 10% and that the annual demand for
the invention is expected to remain constant over the next
twenty years and can be described by the linear demand curve:
P = 200 – Q

We continue to assume that there are zero costs of licensing other than the fixed costs of commercialization, which we
assume, for this example, are equal to $50,000. It can be
shown that an unrestrained patentee will charge a monopoly
price of $100 and produce annual revenues of $10,000 with a
twenty-year annuitized present value of $85,135. With these
prospective profits, the university will take on the cost of commercialization and earn in present value terms an expected
profit of $35,135. The problem with this outcome, however, is
that in this equilibrium, consumer surplus is unduly restricted
by the monopoly overcharge for the full twenty-year period.
The duration auction can mitigate this problem. The reservation bid (derived from Equation 1) of a bidder with commercialization cost of $50,000 will be approximately 7.3 years. If
there are at least two bidders with this commercialization cost,
then consumers of the invention will only have to bear the
monopoly overcharge for this shorter period and then can ex159
Even in the pharmaceutical industry, products often embody multiple distinct inventions. See Ouellette, How Many Patents Does It Take To Make a Drug?,
supra note 30, at 314–315.
160
We analyze a more general (and interactive) linear model in the Appendix.

R

\\jciprod01\productn\C\CRN\102-2\CRN201.txt

310

unknown

Seq: 40

CORNELL LAW REVIEW

17-JAN-17

10:50

[Vol. 102:271

pect to be able to consume the off-patent invention at the competitive price (assumed here to be zero). In this example, social
welfare increases relative to the twenty-year monopoly by
22.6%.161
The revenue cap auction, however, does an even better job
of mitigating the monopoly overcharge problem. The reservation revenue cap bid (derived from Equation 2) of a bidder with
a $50,000 commercialization cost will be approximately 41.3%
lower than the monopoly revenue charged by an unrestrained
patentee. If there are at least two bidders with this cost, then
they can be expected to reduce the cap to this limited revenue
with an associated increase in consumer welfare.162 In this
example, the revenue cap auction increases social welfare relative to the twenty-year monopoly by 47.8%.163
The revenue cap auction in this example improves social
welfare substantially more than duration auction.164 Holding
the rightsholder profits constant, consumers are better off being subjected to a restrained price for more years than to a
monopoly price for fewer years. The intuition for the dominance of revenue cap bidding can be analogized to what economists call Ramsey pricing.165 To generate a certain amount of
tax revenue, the tax structure that will minimize the distortion
consumption effect (read: deadweight loss) will tend to tax as
many goods as possible (so as to create small distortions in a
161
Social welfare is the sum of producer and consumer surplus. In the monopoly pricing equilibrium, the producer surplus has a present value (described
above) of $35,135, while the present value of consumer surplus can be derived in
the Appendix to be $42,568, for social welfare equal to $77,703. In contrast, the
duration auction competition reduces producer surplus to zero but expands the
present value of consumer surplus (as can be derived in the Appendix) to $95,271
(which is the present value of consumer surplus over the initial years of monopoly
($100) pricing and the residual years of competitive ($0) pricing). Thus, the duration auction in this example increases social welfare by $17,568 or 22.6%.
162
Instead of charging the monopoly price of $100, a licensee limited to periodic revenue of $5,873 would (as derived in the appendix) set a price of just
$35.80.
163
The revenue cap auction competition again reduces producer surplus to
zero but expands the present value of consumer surplus (as shown in the appendix) to $114,828 (which is the present value of consumer surplus over twenty
years of restrained (p = 35.8) pricing). Thus, the revenue cap auction in this
example increases social welfare by $37,125 or by 47.8%.
164
The duration auction produced social welfare of $95,271, while the revenue auction produce social welfare of $114,828. This represents an improvement
of approximately 20.5%.
165
See Frank P. Ramsey, A Contribution to the Theory of Taxation, 37 ECON. J.
47, 54–58 (1927); see generally William J. Baumol, Ramsey Pricing, in 4 THE NEW
PALGRAVE: A DICTIONARY OF ECONOMICS 49, 49–51 (John Eatwell et al. eds., 1987)
(reviewing the subsequent literature).
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broad variety of markets).166 If we view each year as a separate
product, then the most efficient way—à la Ramsey—to produce
revenues sufficient to cover the commercialization cost is to
impose some tax on every product. We would not expect to tax
only some of the products. But the duration auction violates
the Ramsey intuition by taxing just the first Y years and then
imposing no “tax” on subsequent years. The revenue cap auction is likely to be more efficient than the duration auction
because it better comports with the Ramsey intuition that
smaller taxes on a broader tax base tend to be less distortionary. In the remaining sections, we focus on the revenue cap
auction exclusively because of its efficiency advantage.
3. Defensive Bidding by Consumers
Until now, we have examined the bidding behavior of nonconsumers of the underlying invention. Non-consumers’ sole
value in winning a commercialization auction comes from the
potential revenues conferred by the limited exclusivity grant
from the government. Consumers of the underlying invention,
however, have an additional rationale for bidding. By winning
the auction, a consumer can avoid the distortionary effect of
being subject to the exclusionary license of another rightsholder. Accordingly, it might be rational for consumer bidders
to bid more aggressively than non-consumer bidders with similar commercialization costs.
To formalize this intuition, this Section begins by deriving
the reservation bid in a revenue cap auction for a monopsonist
bidder (who expects to be the only consumer of the invention)—
an assumption we relax later. A monopsonist’s reservation bid
can be derived from finding the bid at which its payoff from
winning the auction is equal to its payoff from losing the auction. At this level, the monopsonist is indifferent between winning and losing the auction. A monopsonist’s payoff from
losing an auction with a revenue cap, B, is equal to its annuitized consumer surplus of being subject to a rightsholder constrained by the revenue cap.167 A monopsonist’s payoff of
winning the auction is the annuitized consumer surplus of
licensing the invention to itself at a competitive (zero) price
166
This analysis of Ramsey pricing is taken from Ayres & Klemperer, supra
note 143, at 991.
167
A rightsholder constrained to earn a revenue amount strictly less than the
monopoly revenue level can achieve this by charging a price higher than the
monopoly level or a price lower than the monopoly level. We assume that the
rightsholder will prefer to establish a larger presence in the downstream market
and will accordingly choose the more socially efficient lower price.
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minus the costs of undertaking the commercialization. In algebraic terms, the monopsonist’s reserve bid will hence be derived from:
CSB * A(20) = CSC * A(20) – Ci

(3)

where CSB and CSC are, respectively, the consumer surplus for
a particular bid, B, and for the competitive equilibrium and, as
before, A(20) is the twenty-year annuitization rate, and Ci is the
monopsonist’s commercialization costs. Equation 3 can be rewritten as
CSC – CSB = Ci/A(20)

(4)

which has a graphic interpretation in Figure 1:
$

A

B

C
Q

The left-hand side of Equation 4 represents the marginal
increase in consumer welfare from winning the auction.
Graphically, this benefit is equal to the areas of B and C. By
bidding more aggressively—effectively committing to expand
output—the monopsonist bidder can avoid the deadweight loss
(area C) but only by agreeing to take on the costs of commercialization. Graphically, the monopsonist bidder will be indifferent between winning and losing the auction at the point at
which areas B + C equal the annuitized equivalent of its commercialization cost (Ci/A(20)). In contrast, Equation 2 implies
that a non-consuming bidder will only be willing to bid down to
a point at which area B (the periodic licensing revenues) equals
the annuitized equivalent of its commercialization cost (Ci/
A(20)). Because for any given bid areas B + C will always be
greater than simply area B, we can infer that a monopsonist
will always be willing to outbid a non-consuming bidder with
the same commercialization costs.
The willingness of monopsonist bidders to bid more aggressively than similarly situated non-consumers can also be seen
in the foregoing example. While the non-consuming bidder
with a commercialization cost of $50,000 would be willing to
accept an annual revenue cap as low as $5,873 (associated
with a licensing price of $35.80), a monopsonist bidder with the
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same cost of commercialization would be willing to bid as low
as $5,364 (associated with a licensing price of just $31.91).
Because of the monopsonist’s willingness to bid more aggressively than non-consumers with similar costs, it is possible
for monopsonists with higher costs of commercialization to win
the auction. In the foregoing example, a monopsonist with any
cost Ci up to $55,443 will outbid a non-consumer with a
$50,000 commercialization cost. From a social welfare perspective, the possibility that monopsonists with inefficiently
high commercialization costs would take on the duty to commercialize is troubling. But a monopsonist winning the commercialization auction also produces an efficiency advantage of
eliminating the deadweight distortion caused by licensing at a
price above the (zero) competitive price. In our model, these
two efficiency effects exactly offset each other—meaning that
the auction winner will produce the lowest combination of
deadweight and commercialization costs. This surprising result can be seen by considering again Figure 1. The monopsonist bids down to the point where areas B and C equal the
annuitized value of the monopsonist’s commercialization cost.
In contrast, a non-consumer bids down to the point where just
area B equals the annuitized value of its commercialization
cost. But the non-consumer’s overcharge produces deadweight
loss equal to area C. So for either type of bidder the combination of areas B and C is equal to the combination of its annuitized commercialization cost plus the periodic deadweight loss
of any subsequent overpricing.
Thus, happily, the bidder with lowest reservation bid can
be expected to be in aggregate the most efficient commercializer/price-setter. A monopsonist with higher commercialization costs will only be able to outbid a non-consumer if its
social welfare advantage in pricing outweighs its disadvantage
in commercialization.
Of course, monopsony is relatively rare.168 It is natural
therefore to consider the bidding behavior of consumers who
have only a share (si < 1) of the assumed invention demand at
any particular price. For such a consumer, Equation 4 can be
generalized by assessing the bidder’s payoff from just winning
or just losing the auction. If the bidder just loses the auction
(because her reservation bid is epsilon above the winning bid),
168
We do not assume that the monopsonist consumer of the invention is in
turn a monopolist in the downstream market as there may be other means of
producing the downstream product or services that do not require practicing the
invention in question.
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her payoff is si * A(20) * CSB, which equals the present value of
the stream of her share of consumer surplus. If the bidder just
wins the auction (because her reservation bid is epsilon below
the second place bid), her payoff is A(20) * (1 – si) * RB + si *
A(20) * CSc – Ci, which equals the present value of the revenue
the bidder can make from licensing the invention to the other
invention consumers plus the present value of the bidder’s own
consumer surplus of being able to purchase the invention at a
competitive (zero) price minus the costs of commercialization.
Thus, as above, the bidder’s reservation price can be derived
from the equation:
si * A(20) * CSB = A(20) * (1 – si) * RB + si * A(20) * CSc – Ci (5)
Equation 5 nicely nests Equations 2 and 3. When s = 0,
Equation 5 simplifies to Equation 2, A(20) * RB = Ci, the nonconsumer’s reservation bid equation. And when s = 1, Equation 5 simplifies to Equation 3, A(20) * CSB = A(20) * CSC – Ci,
the monopsony reservation bid equation.
In the Appendix, we derive a closed-form solution for the
reservation bid implied by Equation 5. But here Table 3 instead shows how in our foregoing numeric example, key outcomes change as a bidder’s share of the downstream market
varies:
TABLE 3. EFFECT OF CHANGING BIDDER’S SHARE OF
DOWNSTREAM MARKET.
0%
Reserve Bid
Pm
Qm
PV(CS)
% Patent
DWL Eliminated

20%

40%

60%

80%

100%

$5,873
$5,752
$5,642
$5,542
$5,449
$5,364
$36
$35
$34
$33
$33
$32
164
165
166
167
167
168
$114,828 $116,142 $117,321 $118,391 $119,370 $120,271
56.6%

57.6%

58.5%

59.4%

60.1%

60.8%

As expected from nesting, the reserve bid varies from the
non-consumer’s reservation of $5873 when s = 0 to the
monoposonist’s reserve of $5364 when s = 1. Moreover,
following the logic of defensive bidding discussed above, the
Table shows that the larger the bidder’s share of the
downstream market, the more aggressively she is willing to bid,
and the larger the proportion of the deadweight loss of
monopoly that is eliminated. Our earlier argument—that the
lowest bidder will produce the lowest combination of
commercialization and deadweight loss—also extends to the
more general case of bidders with intermediate market shares.
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The nesting reservation bid Equation 5 can be rewritten in
terms of the areas depicted in Figure 1 to be:
(1 – si) * RB + si * CSC – si * CSB = Ci / A(20)
(1 – si) * (Area B) + si * (Area A + B + C) – si * (Area A) = Ci / A(20)
(Area B) + s * (Area C) = Ci / a(20)

Intuitively, the bidder is willing to bid down until the
annuitized marginal cost of winning the auction, Ci/A(20), is
equal to the marginal benefit (which is equal to its benefit from
avoiding the licensing, s * (Areas B + C), plus its benefit from
selling to other consumers, (1 – s) * (Area B). But at this
reservation price, the bidder would be producing deadweight
loss of (1 – s) * (Area C). Once again at the reservation price,
the combined deadweight and commercialization costs will be
equal to Area B + C. So for bidders with any share, the winner
of the auction may not be expected to minimize the costs of
commercialization or might not minimize the deadweight loss
of patent overpricing, but happily can be expected to minimize
the combination of these two costs.
Since in many cases efficient commercialization can be
accomplished by separately contracting with the lowest cost
commercializer, our analysis suggests that invention
consumers with larger market shares would have a structural
advantage in commercialization auctions because of their
willingness to bid more aggressively to “defensively” avoid the
deadweight loss of patent overcharges.
The larger the bidder’s market share, the more winning
eliminates the overcharge deadweight loss. The social welfare
advantage of the monopsonist bidder described above might be
emulated in a legal regime that allowed consumers to collude in
their bidding strategy. A consumer cooperative might be
willing to emulate the benefits of a monopsonist—eliminating
all deadweight loss. But one might also imagine examples in
which collusion among consumer bidders suppressed
competition and thereby decreased social welfare. For
example, imagine a world in which the university and all other
non-producers have relatively high commercialization costs
and that without collusion two producers each with 10%
shares and extremely low commercialization costs would bid
the revenue cap down to virtually nothing. In such
circumstances, we might worry that collusion by the low cost
bidders would not lead them to bid more aggressively but
instead suppress bidding competition so that they could
overcharge the remainder of the downstream market.
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Stepping back, our modeling exercise has produced the
following takeaways:
1. A commercialization auction can produce zero
exclusivity outcomes and more generally reveal to
government the amount of exclusivity needed to
induce commercialization.
2. Revenue cap bidding (or price cap bidding) is more
efficient than duration bidding, though often less
administratively feasible.
3. Defensive bidding by consumers will be more
aggressive than by non-consumers with equal
commercialization costs.
4. The winning bidder will tend to give rise to the lowest
combined commercialization and deadweight costs.
5. Bidder collusion by consumers is good if it tends to
reduce deadweight loss (and lead to more aggressive
bidding), but it is bad if it takes away potential
competitors (and leads to less aggressive bidding).
Richard Posner long ago argued that auction-like competition
for legally created market power would tend to transform
monopoly profits into additional deadweight losses.169 In
Posner’s model, the inefficiency of acquiring the governmentsponsored monopoly increased to the deadweight loss of Area B
as well as the traditional deadweight loss triangle (Area C).170
Our strikingly happier result stems from changing the basis of
competition. Instead of competing over the most lavish
lobbying expenses, bidders in our model compete by
committing to commercialize effectively a lower compulsory
license fee.
III
IMPLEMENTING THE MARKET TEST
For readers who are now convinced that a market test for
Bayh–Dole patents is a good idea—or is at least worth trying
until more evidence is developed—the next question is: how do
we make it happen? In subpart III.A, we explore the possible
courses for three different actors in the current system: universities, federal grant agencies, and Congress. A well-motivated
member within any one of them could make progress toward
using the market test to enhance social welfare. Subpart III.B
169
See Richard A. Posner, The Social Costs of Monopoly and Regulation, 83 J.
POL. ECON. 807, 809–811 (1975).
170
See id.
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then discusses some details of implementation and possibilities to avoid gaming.
A. Institutional Actors
1. Universities
Some universities might be inspired to implement the market
test on their own or might be spurred to do so by student
groups and other constituents focused on access to university
technologies. A number of scholars have urged universities to
focus on the public interest when designing their patenting and
licensing policies.171
One might be skeptical that any university would take this
step, especially given the stories of increasing litigiousness and
focus on monetization described in the Introduction.172 But
there have been noteworthy instances in which universities
have used their patent rights for social good rather than maximizing profit, including at Yale:
[I]n 1990 Yale patented the use of the drug stavudine (d4T) to
treat HIV and granted an exclusive license to Bristol-Myers
Squibb. Under the trade name Zerit, stavudine became a key
drug for treating HIV. With a cost of over $1600 per year,
however, it was inaccessible to most patients in developing
countries. Médecins Sans Frontières (MSF) wanted to distribute stavudine in South Africa. An Indian manufacturer
offered to supply the drug for $40 per year, but MSF was
unable to accept because Yale had patented stavudine in
South Africa. With the help of Yale Law students Amy
Kapczynski (now a law professor) and Marco Simons, MSF
approached Yale, which began negotiating with Bristol-Myers
Squibb. After the issue was publicized in the New York
Times, Bristol-Myers Squibb announced that it would not
enforce the stavudine patent in South Africa and that it
would sell Zerit in sub-Saharan Africa for $55 per year.173
171
See, e.g., Amy Kapczynski et al., Addressing Global Health Inequities: An
Open Licensing Approach for University Innovations, 20 BERKELEY TECH. L.J. 1031,
1078–90 (2005); Lemley, Are Universities Patent Trolls?, supra note 9, at 625–28;
Ouellette, Addressing the Green Patent Global Deadlock, supra note 6, at 1735;
Ouellette, How Many Patents Does It Take To Make a Drug?, supra note 30, at
321–22.
172
See supra notes 6–24 and accompanying text; see also Jay P. Kesan,
Transferring Innovation, 77 FORDHAM L. REV. 2169, 2207 (2009) (“University tech
transfer activities continue to be predominantly patent-centric and revenue
driven with a single-minded focus on licensing income and reimbursement for
legal expenses.”).
173
Ouellette, How Many Patents Does It Take To Make a Drug?, supra note 30,
at 309 (footnotes omitted).
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This campaign led to the establishment of the activist group
Universities Allied for Essential Medicines (UAEM), which has
pushed universities to consider how their patent policies affect
global health, and which helped craft—and convince universities to sign—two licensing policy statements related to the dissemination of medical technologies.174 UAEM now issues an
annual report card that grades universities on their global
health impact in an effort to increase transparency about university policies.175 In the 2015 version, Johns Hopkins topped
the list with an overall A–, our institutions—Yale and Stanford—received a B and a B–, and grades ran all the way down to
F (earned by Wake Forest University and the University of
Cincinnati).176
These student campaigns have focused on access to
pharmaceuticals in in low-income countries—an industry in
which, as we have explained, having at least some exclusive
patent rights is important for commercialization.177 The case
for reduced reliance on exclusive rights or costly nonexclusive
licenses is even stronger for inventions that would be commercialized even if they were not patented, and access-focused
student groups might consider turning their attention to university patents on non-pharmaceutical inventions.
The negative publicity universities have received about behaving like “patent trolls” might actually make it easier to
change their behavior.178 If a few prominent universities implement some version of our market test and show it is feasible,
it could encourage others or spur legislation making this policy
174
See id. at 309–11 (describing the 2007 “Nine Points” statement, CAL. INST.
OF TECH. ET AL., supra note 137, and ASS’N OF UNIV. TECH. MANAGERS ET AL., STATEMENT OF PRINCIPLES AND STRATEGIES FOR THE EQUITABLE DISSEMINATION OF MEDICAL
TECHNOLOGIES (2009), http://otd.harvard.edu/upload/files/Global_Access_State

ment_of_Principles.pdf [https://perma.cc/2CTA-9L6X]).
175
Donald G. McNeil Jr., University Grades Are Mixed on Research for the
Poor, N.Y. TIMES, May 12, 2015, at D3, http://www.nytimes.com/2015/05/12/
health/university-grades-are-mixed-on-research-for-the-poor.html [https://
perma.cc/7GCY-NQAB].
176
University Report Card: Global Equity & Biomedical Research, UNIV. ALLIED
FOR ESSENTIAL MED., http://globalhealthgrades.org [https://perma.cc/LB48VEKB]. There are separate subgrades focused on “access,” which may be a better
metric for those interested in patent policies. UAEM might consider adding points
to the grade of a university that implements of a policy of patenting and licensing
inventions under the conditions described in this article.
177
See supra notes 28–29 and accompanying text.
178
Cf. Lemley, Are Universities Patent Trolls?, supra note 9, at 611–12 (explaining how universities are increasingly viewed as patent trolls, and arguing
that they “should take a broader view of their role in technology transfer” rather
than engaging in the “bad acts” that “concern[ ] us about trolls”).
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mandatory.179 Ideally, universities that test the market test
should do so on a randomized basis and should develop nonpatent-related metrics to track the extent to which inventions
that are not patented are commercialized.180
A university that chose to unilaterally implement the market test would not run afoul of the Bayh–Dole Act. Bayh–Dole
gives universities the right but not the obligation to patent federally funded inventions.181 Universities must disclose federally funded inventions to the agency “within a reasonable time”
and must decide whether to patent the invention “within two
years after disclosure,” though this time may be lengthened by
the agency or shortened if a publication or other public disclosure imposes a closer deadline on when the invention may be
patented.182 In practice, even these minimal requirements are
not strictly followed, with many patents arising from federal
funding neither being disclosed to the agency nor containing
required government-interest statements.183
If a university elects not to patent an invention, the agency
has the right to take title.184 But if the university made this
choice because it showed that exclusivity is unnecessary for
commercialization, it seems unlikely to us that the agency
would intervene.
If a university elects to patent an invention, the Bayh–Dole
Act does not require the university use any particular licensing
structure. The patent can be licensed exclusively or nonexclusively; for free or for a hefty fee. The only obligation is that if
the patent is licensed exclusively, the invention should be manufactured “substantially in the United States,” if possible.185
Our market test is certainly permissible under the statutory
requirements. As discussed below, if the university does not
take “effective steps to achieve practical application of the subject invention,” the agency may intervene to issue additional
179
One structural mechanism for this private ordering might be the coordinated patent pledges described in Jorge L. Contreras, Patent Pledges, 47 ARIZ. ST.
L.J. 543, 567–69 (2015).
180
See generally Michael Abramowicz, Ian Ayres, & Yair Listokin, Randomizing Law, 159 U. PA. L. REV. 929 (2011) (advocating greater use of randomized
policy testing); Ouellette, Patent Experimentalism, supra note 36, 87–104 (describing the benefits of policy randomization in the patent context).
181
35 U.S.C. § 202 (2012).
182
35 U.S.C. § 202(c)(1)–(2). The standard patent rights clauses appear at 37
C.F.R. § 401.14.
183
See Arti K. Rai & Bhaven N. Sampat, Accountability in Patenting of Federally Funded Research, 30 NATURE BIOTECHNOLOGY 953, 954–55 (2012). But “universities are improving their compliance with reporting obligations.” Id. at 955.
184
35 U.S.C. § 202(c)(2).
185
35 U.S.C. § 204.
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licenses.186 But the market test is specifically designed to
achieve practical application in the most efficient manner.
2. Grant Agencies
The agencies responsible for the largest amount of public
research funding are Health and Human Services (50%, primarily distributed through the NIH), the Department of Energy
(12%), the Department of Defense (10%), the National Aeronautics and Space Administration (NASA) (9%), and the National
Science Foundation (NSF) (8%).187 These agencies could play a
significant role in implementing the Bayh–Dole Act in a manner
more closely aligned with its statutory goals.
As noted in the Introduction, federal agencies already have
statutory authority to limit the patent rights of grant recipients.
There are two key statutory hooks. First, under § 202 of the
Bayh–Dole Act, a funding agreement may limit a grant recipient’s ability to patent “in exceptional circumstances when it is
determined by the agency that restriction or elimination of the
right to retain title to any subject invention will better promote
the policy and objectives of this chapter . . . .”188 Recall that the
Act begins by noting that “[i]t is the policy and objective of the
Congress to use the patent system to promote the utilization of
inventions arising from federally supported research or development . . . .”189 Using the market test to determine those
circumstances in which utilization of federally funded inventions would be increased through less exclusivity would seem
to fall squarely within this goal and would provide an objective
means of determining whether the circumstances are such that
an “exception” to the Bayh–Dole right to patent should be
made. Under § 202, agencies funding non-pharmaceutical research might routinely include in funding agreements provisions requiring grantees to conduct an exclusivity auction in
the exceptional circumstances that an interested third-party
licensee objects to a proposed exclusive license and triggers the
market-test mechanism.190
The second statutory provision that allows agencies to limit
university patent rights is § 203, which states that when a
grant recipient has already patented an invention, agencies
186
187
188
189
190

35 U.S.C. § 203(a)(1).
NAT’L SCI. FOUND., supra note 1, at 4–86.
35 U.S.C. § 202(a)(ii).
35 U.S.C. § 200.
See supra note 145 and accompanying text.
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may sometimes exercise “march-in rights.”191 Specifically, the
Act permits agencies “to require the contractor . . . to grant a
nonexclusive, partially exclusive, or exclusive license in any
field of use . . . upon terms that are reasonable under the
circumstances,” or “to grant such a license itself,” if the agency
determines that any one of several conditions are satisfied.192
For example, agencies can compel licensing if the contractor
“has not taken, or is not expected to take within a reasonable
time, effective steps to achieve practical application of the subject invention,”193 where “practical application” is defined as
manufacture or practice under conditions such that the invention’s “benefits are . . . available to the public on reasonable
terms.”194 Agencies can also exercise march-in rights where
“necessary to alleviate health or safety needs.”195 March-in
rights may also be used when “necessary to meet requirements
for public use specified by Federal regulations.”196
There have been only five publicized petitions for agencies
to exercise their march-in rights, all filed with the NIH, and in
each case the NIH dismissed the petition without progressing
to the march-in proceeding stage.197 The regulations governing
march-in proceedings have thus never been used, much less
tested in court.198 While we favor ex ante application of the
market test via § 202, an agency could use its § 203 march-in
authority to implement a version of our market test. If a federally funded invention is patented and licensed in a way that
threatens substantial constraints on quantity, an agency could
exercise its march-in rights if the university failed to show with
market-test evidence that exclusivity was necessary to promote
the commercialization goals of the Bayh–Dole Act. A university
that failed to undertake such a test would run the risk of failing
this ex post inquiry. Without such evidence, an agency could
reasonably conclude that the invention is not “available to the
public on reasonable terms.”199
191

35 U.S.C. § 203.
35 U.S.C. § 203(a).
193
35 U.S.C. § 203(a)(1).
194
35 U.S.C. § 201(f).
195
35 U.S.C. § 203(a)(2).
196
35 U.S.C. § 203(a)(3).
197
See Whalen, supra note 27, at 1099–1106. For the NIH responses, see
Policies & Reports, NAT’L INSTS. HEALTH, http://www.ott.nih.gov/policies-reports
[https://perma.cc/5Q6G-AM5Z].
198
See 37 C.F.R. § 401.6 (march-in regulations); see also 35 U.S.C. § 203(a)
(stating that march-in rights shall be used “in accordance with such procedures
as are provided in regulations promulgated hereunder”).
199
35 U.S.C. § 201(f).
192
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It might seem unlikely that agencies that have never exercised march-in rights will now decide to do so, but if some
universities continue to exercise their patent rights in ways
that are hard to square with the public interest,200 agencies
might find it more politically palatable to step in.201 Furthermore, some of the reluctance to use ex post march-in rights
after a license is negotiated may stem from concerns about
upsetting the licensee’s reliance interests, which would not be
a concern with our market test. Indeed, because some of the
benefit from the market test is concentrated with private parties—those who would want to trigger exclusivity auctions to
prevent competitors from receiving exclusive licenses—publicchoice theory suggests it should be more likely to be implemented than march-in rights, for which the benefits are more
broadly distributed among the public.
A third way agencies could promote use of the market test
is through their ex ante control over which projects get funded
in the first place.202 Just as agencies like the NSF require
universities to have conflict-of-interest policies,203 they could
require universities to have socially responsible licensing policies that include a market test requirement. The NSF created
its conflict-of-interest policies (as well as many other policies
governing its grant awards) under its broad statutory authority
“to prescribe such rules and regulations as it deems necessary
governing the manner of its operations . . . .”204
Alternatively, agencies could include patenting and licensing considerations in individual project reviews. For example,
the NSF reviews projects not just for intellectual merit but also
for “broader impacts,” i.e., “the potential to benefit society,”205
which includes dissemination—the NSF “encourages grantees
to share software and inventions . . . and otherwise to make the
200

See supra notes 7–14 and accompanying text.
See, for example, the recent letter from over fifty congressmen urging the
NIH to exercise its march-in rights. Letter from Lloyd Doggett et al., supra note
29.
202
This idea was first proposed by Ouellette, Addressing the Green Patent
Global Deadlock, supra note 6, at 1736–37.
203
See NAT’L SCI. FOUND., PROPOSAL AND AWARD POLICIES AND PROCEDURES GUIDE
IV-1 (2016), http://www.nsf.gov/pubs/policydocs/pappguide/nsf16001?/
nsf16_1.pdf [https://perma.cc/56PG-ZCG6]. This requirement for conflict-of-interest policies became effective in 1995 after a notice-and-comment period. 59
Fed. Reg. 33308 (June 28, 1994).
204
42 U.S.C. § 1870(a) (2012). For other grant policies, see NAT’L SCI. FOUND.,
supra note 203, at I-1 (referring to policies falling within the authority of § 1870).
205
NAT’L SCI. FOUND., supra note 203, at III-2.
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innovations . . . widely useful and useable.”206 If the NSF
makes clear that commitment to use a market test to disseminate the invention is a positive factor under “broader impacts”
review, it would bring patent and licensing concerns to the
attention of the researchers applying for grants and not just
university administrators.
Finally, federal agencies could help with some of the practical details of implementing and advertising patent auctions. A
centralized website listing new university patents and auction
information—perhaps run by a grant agency or by the Patent
and Trademark Office (PTO)—would help spread information
about available technologies to prospective commercializers.
Bayh–Dole patents are already required to contain “a statement specifying that the invention was made with Government
support and that the Government has certain rights in the
invention.”207 Compiling these patents in a single database
would be quite straightforward; even better would be a requirement that universities update the database with information
about pending applications and ongoing auctions. We return
to these practical details in subpart III.B.
3. Congress
As explained in the prior two sections, implementing our
market test proposal does not require legislative change: either
universities or federal grant agencies could accomplish the
main goals. But a Bayh–Dole amendment would make such a
change easier and more uniform.
Most simply, it would be helpful if the statute explicitly
stated that federally funded research should be exclusively licensed only when necessary for commercialization and can
never be nonexclusively licensed for more than the cost of patenting, and leaving the details of implementation to agencies.
Congress might also explicitly direct an agency to implement a
randomized test of the market test and to study the resulting
commercialization outcomes.208
206
NAT’L SCI. FOUND., MERIT REVIEW BROADER IMPACTS CRITERION: REPRESENTATIVE
ACTIVITIES (2002), http://www.nsf.gov/pubs/2002/nsf022/bicexamples.pdf
[https://perma.cc/B97V-S5T8].
207
35 U.S.C. § 202(c)(6) (2012). As noted, this requirement is not always
followed, but compliance is improving. See supra note 183 and accompanying
text. The PTO might improve compliance by affirmatively asking university applicants whether an invention stems from federal funds.
208
See supra note 180 and accompanying text.
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To be sure, given the success of the university lobby in
legislative debates over patent reform,209 such a change may
seem unlikely. But perhaps if universities continue to be
viewed increasingly as patent trolls rather than as good actors
in the system,210 there will be more momentum for reform.
B. Timing, Enforcement, and Gaming
Thus far, we’ve explained that at least three independent
institutional actors—universities, federal grant agencies, and
Congress—could implement the market test. But how should
they implement it, and how might they prevent other actors
who are less enthusiastic about the idea from undermining the
system?
First, potential commercializers should be able to find out
about new university technologies as quickly as possible. In
the case of high-profile technologies such as CRISPR,211 the
relevant firms will likely hear about the inventions from scientific publications and conferences. But a more general
database of new inventions would aid this dissemination process and reduce search costs. The eighteen-month delay
before patent applications are published makes little sense for
university research, which scientists are eager to publish anyway.212 Bayh–Dole patent applications should be published in
a central database at the time of filing.213
The exclusivity auction could begin at this time—perhaps
in response to a trigger from an interested licensee214—and
could run while the application is being prosecuted at the PTO.
This process typically takes many months: over the past decade, the median patent has spent thirty to forty months in
prosecution.215 Prospective commercializers would enter the
auction by submitting bids with the minimum amount of ex209
For example, the America Invents Act specified that a university is a “micro
entity” entitled to reduced filing fees. 35 U.S.C. § 123(d); see also Andrew Ramonas, University Lobby Push, NAT’L L.J. (Apr. 7, 2014), http://www.nationallaw
journal.com/id=1202649803262/University-Lobby-Push [https://perma.cc/
U64J-U236] (“More than three dozen universities are spending millions of dollars
on Washington lobbyists to help shape patent litigation reform . . . .”).
210
See supra notes 8–15 and accompanying text.
211
See supra notes 33–35 and accompanying text.
212
See Ouellette, Do Patents Disclose Useful Information?, supra note 88, at
582–83.
213
As noted previously, such a database could be administered by the PTO or
by a federal grant agency. See supra section III.A.2.
214
See supra note 145 and accompanying text.
215
See Dennis Crouch, Median Patent Prosecution Pendency, PATENTLY-O
(June 15, 2015), http://patentlyo.com/patent/2015/06/patent-prosecution-pen
dency.html [https://perma.cc/D7TQ-PVR9].

R
R
R

R

\\jciprod01\productn\C\CRN\102-2\CRN201.txt

2017]

unknown

Seq: 55

17-JAN-17

A MARKET TEST FOR BAYH–DOLE PATENTS

10:50

325

clusivity for which they would commercialize the invention,
along with sufficient details to convince a reasonable observer
of the firm’s likelihood of success. For example, in a duration
auction, bids would be the fewest years (or months) of exclusivity for which the firm would commercialize. If the auction is
run as a Vickrey auction, as discussed above, bidders would
submit sealed bids, and the winning firm—the one bidding the
smallest amount of exclusivity—would pay the second-lowest
bid.216 If only one firm is willing to commercialize, it could have
an exclusive license for the full remaining patent term.
We do not know the optimal length of the auction period,
and it likely varies by technological field. For some inventions
with numerous applications, it may also be worth conducting
separate auctions in different fields, just as universities currently offer field-specific patent licenses. Agencies regulating
how the market test will be implemented may wish to experiment with different time periods, ideally using randomized
trials.217
The requirement to publish inventions and to initiate the
market test at the time of filing a patent application could be
required either by statute or as part of agency-funding agreements. Universities could also be required to stop pursuing the
patent if there is rapid commercialization without exclusivity.
A condition of issuing a Bayh–Dole patent could be an affirmation from the applicant that the invention has not already been
put into practical application. If universities seem reluctant to
implement these patenting and licensing practices, tying evidence of cooperation with such requirements to future grant
funding would provide a strong incentive.218
To ensure that the winner of a market test in fact commercializes the invention in good faith, the licenses can use due
diligence milestones, which are already common in patent
commercialization contracts to “ensur[e] that . . . licensees will
develop and market the licensed products in a timely manner”
and “will not sit on the licensed technology, for example, for

216

See supra note 150 and accompanying text.
See supra note 180 and accompanying text.
218
There are numerous ways in which reluctant universities might engage in
strategic behavior to maximize their own returns, but this might not be worse
than the status quo. For example, if universities strategically file narrower patents that they are more likely to be able to exclusively license, then this still would
be an improvement: these exclusive licenses would create less deadweight loss
than exclusive licenses on broader patents would.
217
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defensive purposes.”219 The intended outcome could be based
on the current statutory language of the Bayh–Dole Act for
achieving “practical application of the subject invention”:220
The term “practical application” means to manufacture in the
case of a composition or product, to practice in the case of a
process or method, or to operate in the case of a machine or
system; and, in each case, under such conditions as to establish that the invention is being utilized and that its benefits
are to the extent permitted by law or Government regulations
available to the public on reasonable terms.221

The duty to exercise diligence in commercializing could be
based on a legal standard similar to whether you exercised
reasonable diligence in reducing an invention to practice.222
Initial commercializers who fail on their promise to commercialize could be made to pay expectation damages to the patentee, and the patentee could be allowed to re-auction the
invention if commercialization benchmarks are not met. Evidence of egregious bad faith might subject initial licensees to
more significant penalties.223
Even with these diligence requirements, one might be concerned that commercialization is not a binary option: even if a
firm will commercialize a Bayh–Dole patent in good faith and
make the invention available to the public on reasonable terms,
it is possible that a firm with greater exclusivity may have
somehow commercialized the invention better, such as by introducing a product with higher quality or by commercializing
it faster.224 Of course, these benefits must be weighed against
219
Theodore A. Wood, Launching Patent Licensing for an Emerging Company,
30 U. DAYTON L. REV. 265, 270 (2004). Ted Sichelman discusses the related
problem of ensuring that recipients of his proposed “commercialization patent”
actually commercialize the invention, but note that he is focused on inventions
that no one wants to commercialize in the current system, whereas we are focused
on inventions that many firms want to commercialize. Sichelman, supra note 69,
at 402–11.
220
35 U.S.C. § 203(a)(1) (2012).
221
35 U.S.C. § 201(f).
222
See generally Brown v. Barbacid, 436 F.3d 1376, 1378–82 (Fed. Cir. 2006)
(reviewing the reasonable diligence standard).
223
But enlightened tests of due diligence would need to balance the risk that
penalties would have an ex ante chilling effect on the willingness of potential
licensees to take on the duty of commercializing the invention. Initial licensees
can only profit from a license if they are able to bring the product to market. For
an overview of the tradeoffs between specifying contractual provisions at the time
of contracting versus during later litigation, see generally Robert E. Scott &
George G. Triantis, Anticipating Litigation in Contract Design, 115 YALE L.J. 814
(2006).
224
Cf. Michael Risch, Licensing Acquired Patents, 21 GEO. MASON L. REV. 979,
1009–12 (2014) (arguing that licensing can lead to earlier commercialization).

R

\\jciprod01\productn\C\CRN\102-2\CRN201.txt

2017]

unknown

Seq: 57

17-JAN-17

A MARKET TEST FOR BAYH–DOLE PATENTS

10:50

327

the associated deadweight loss costs—having an invention
commercialized a couple of years sooner is likely not worth an
additional decade of monopoly pricing.225 Furthermore, this
concern can be ameliorated by allowing the university (potentially in concert with a potential exclusive licensee) to set due
diligence milestones for commercialization that better assure
heightened quality. Alternatively, when commercialization is
readily quantifiable, bidders might compete on how much commercialization they will do for a certain amount of exclusivity.226 In circumstances where the potential differential in
commercialization quality looms especially large, grant agreements might waive the market test duty. But even when quality is important, follow-on licensees under our proposal will
have free access to practice the invention and will be firstmovers with regard to commercialization improvements.
We think the most concerning potential gaming of our market test system would be an incumbent firm that seeks to prevent market entry of a competing technology. This problem
seems most likely to appear in the pharmaceutical context,
given the high stakes.227 For example, if a firm has a monopoly
over treatment for a certain disease and seeks to prevent a new
drug from competing with its existing product, the firm might
agree to commercialize the new drug for free (or for the lowest
number of years of exclusivity in an auction) and then fail to
conduct clinical trials in good faith. This situation could also
occur outside the pharmaceutical context whenever an incumbent firm seeks to prevent market entry of a competing
technology.
225
See Michael Abramowicz & John F. Duffy, The Inducement Standard of
Patentability, 120 YALE L.J. 1590, 1627 (2011) [hereinafter Abramowicz & Duffy,
The Inducement Standard of Patentability] (explaining that patents should not be
granted if they accelerate invention by a period for which “the social benefits of the
invention’s existing for that time period are equal to [or less than] the social costs
of patent protection for the patent term minus that period”).
226
Bidders could also compete on some combination of exclusivity and commercialization. The tradeoffs are similar to those discussed in the literature on
price versus quantities. See generally Martin L. Weitzman, Prices vs. Quantities,
41 REV. ECON. STUD. 477 (1974).
227
See supra note 28 and accompanying text. For examples of the vigor with
which brand-name pharmaceutical companies will protect their monopolies, see
FTC v. Actavis, Inc., 133 S. Ct. 2223, 2229 (2013), in which the brand-name
company paid over $200 million to generic firms that were challenging its patent
to get them to drop the suit and stay off the market, and Caraco Pharm. Labs.,
Ltd. v. Novo Nordisk A/S, 132 S. Ct. 1670, 1679–82 (2012), in which the brandname company incorrectly changed its patent information filed with the Food and
Drug Administration (claiming that its patent covered a use of its drug that it did
not) and then argued that a generic challenger had no means of correcting this
filing.
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To deter such behavior, it may be worth having a presumption against licensing Bayh–Dole patents to firms that already
market a product that competes with the new invention. Additionally, this kind of bad-faith behavior by incumbent firms
may be deterred by antitrust review. Exclusive licenses to
medical patents are regarded as acquisitions for purposes of
premerger reviews by the Federal Trade Commission.228 Some
licenses might not meet the notification thresholds; for 2016,
premerger notification is only required for transactions valued
at least at $78.2 million.229 Congress could consider decreasing these reporting thresholds for exclusive licenses to
Bayh–Dole patents.
To address the opposite problem of too much exclusivity
rather than too little, Congress might bar a Bayh–Dole licensee
from suing any other firms who commercialize the invention
before they do. The economic analysis here is similar to the
case for an independent invention defense from patent infringement: if patents are meant to incentivize invention, then
they should not be wielded against those who independently
created the invention without the inducement of a patent.230
Analogously, when the main function of patents is to promote
commercialization (as seems likely for most Bayh–Dole patents), then they should not be used against firms that commercialize without the incentive of exclusive rights. In fact, the
case for an “earlier commercializer” defense is even stronger
than the case for an independent invention defense given that
successful commercialization should be publicly visible, leading to fewer evidentiary problems.
Those implementing our market test can experiment with
many other options for better aligning universities’ incentives
with the goal of preventing commercialization gaming by licensees. For example, it may be worthwhile to give technology
228
See 15 U.S.C. § 18a (2012) (specifying that certain asset acquisitions may
not be executed unless notification with the Federal Trade Commission is filed
and a specified waiting period has expired); 16 C.F.R. § 801.2(g)(2-3) (“The transfer of patent rights covered by this paragraph constitutes an asset acquisition . . .
if all commercially significant rights to a patent . . . for any therapeutic area (or
specific indication within a therapeutic area) are transferred to another entity.”).
229
Federal Trade Commission, Revised Jurisdictional Thresholds for Section
7A of the Clayton Act, 81 Fed. Reg. 4299, 4300 (Jan. 26, 2016).
230
See Samson Vermont, Independent Invention as a Defense to Patent Infringement, 105 MICH. L. REV. 475, 493–99 (2006); see also Mark A. Lemley,
Should Patent Infringement Require Proof of Copying?, 105 MICH. L. REV. 1525,
1527–32 (2007) (explaining the merits of Vermont’s proposal); Abramowicz &
Duffy, The Inducement Standard of Patentability, supra note 225, at 1677 (arguing
that independent invention should weigh heavily in favor of finding a patent to be
obvious).
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transfer offices an incentive to track utilization of university
inventions outside the patent system. As noted above, academic researchers often seem strongly motivated by attribution
and the corresponding increase in credibility,231 so they may be
highly motivated to cooperate if they receive credit for certified
instances of commercialization of their inventions. It might
also be worth offering a prize of additional research funds to
universities that are the most successful at achieving widespread dissemination of their inventions or to allow universities
to charge nominal licensee fees potentially up to some modest
overall revenue cap to their nonexclusive licensees. Universities can be enlisted in policing commercialization without
maintaining their current monopolist status.232
Finally, policymakers and universities might consider
whether third-party firms might be more effective at any stages
of this process. Private firms that aggregate patents from multiple universities might be more effective than individual technology transfer offices at conducting the market test we
describe. And third-party auditors could be used to certify that
inventions actually are available to the public on reasonable
terms, or to help quantify technology transfer outside the patent system for the commercialization prize suggested above.233
We do not claim to have the solution to all of the logistical
problems that might arise with implementation of the market
test, which is why we think it is important to begin by testing
the market test at a few universities. Undoubtedly, agency
regulations informed by experience would need to evolve. But
the potential gains from reducing the needless output restrictions worked by many Bayh–Dole patents makes the case for
trying to harness the willingness of market actors to bring inventions to the market on a more competitive basis.

231
See supra note 60 and accompanying text. For a more general discussion
of how attribution is important to creators and how IP law might respond, see
Jeanne C. Fromer, Expressive Incentives in Intellectual Property, 98 VA. L. REV.
1745, 1790–98 (2012).
232
This carrot of a prize for evidence of successful dissemination might, as
noted above, be tied to the stick of decreased grant funding for universities that
seem to be avoiding implementation, whether strategically or lazily. See generally
Ian Ayres & Amy Kapczynski, Innovation Sticks: The Limited Case for Penalizing
Failures To Innovate, 82 U. CHI. L. REV. 1781 (2015) (discussing the use of both
carrots and sticks as innovation incentives).
233
Cf. Michael Abramowicz & John F. Duffy, Ending the Patenting Monopoly,
157 U. PA. L. REV. 1541, 1582 (2009) (explaining how to provide appropriate
incentives for private patent examination firms, such as by conducting random
government audits).
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CONCLUSION
This Article is our attempt to “mend, not end” the Bayh–Dole
Act. In passing this statute, Congress was right that there are
many contexts where socially valuable inventions would be
“gathering dust” without the ability to grant initial commercializers exclusive licenses. No pharmaceutical producers will
spend tens or hundreds of millions of dollars on human subject
testing without such protection. But many other inventions do
not need a promise of exclusivity to be brought to market.
Stanford’s widely licensed patents on early recombinant DNA
technology are an especially vivid example, where scores of
licensees were willing to make the technology commercially applicable, but these patents are not outliers.234
The problem is that for many government-funded inventions, lawmakers lack the requisite information and expertise
to determine whether exclusive patent grants are necessary to
incentivize commercialization. This problem is endemic to
many aspects of patent law. As a theoretical matter, it might be
better to have different patent lengths for different industries,235 but informationally constrained lawmakers often need
to regulate with blunt, one-size-fits-all rules.236
The question of whether Bayh–Dole patents can be commercialized without exclusivity, we argue, is one instance in
which this informational gap can be filled. Universities can
simply find out whether any firms are willing to commercialize
the invention in exchange for a free nonexclusive license or for
an exclusive license for less than the full patent term. Our
proposed market test auction leverages competition among potential commercializers to tell funding agencies how much exclusivity is really needed to achieve practical application of an
invention.
We hope that even the readers who are most skeptical of an
auction mechanism will at least agree on this: if commercialization theory is the justification for university patents, then those
patents that are nonexclusively licensed in ways that do not
234

See supra notes 10–16 and accompanying text.
Many patent scholars have proposed such a regime. See, e.g., Benjamin N.
Roin, The Case for Tailoring Patent Awards Based on Time-to-Market, 61 UCLA L.
REV. 672 (2014). Dan Burk and Mark Lemley have argued that courts already
provide significant industry-specific tailoring. Dan L. Burk & Mark A. Lemley,
Policy Levers in Patent Law, 89 VA. L. REV. 1575 (2003).
236
When the government does have sufficient information to determine the
optimal reward for each invention, it is generally better to rely on grants or prizes.
See Hemel & Ouellette, Beyond the Patent–Prizes Debate, supra note 32, at
327–32.
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constrain quantity should not have been sought at all. The
licensing revenues and attendant deadweight losses associated
with such patents were unnecessary because these inventions
were commercialized without an exclusive promise.237 If there
turn out to be few inventions that firms are willing to commit to
commercialize for less than full exclusive patent rights, then
our proposal would change little from the status quo aside from
the administrative costs of experimenting with some of these
auctions—such inventions could be exclusively licensed as
usual. But if our market test is successful at finding inventions for which exclusive rights are not needed for commercialization, then it could lead to significant savings for the public
and increased access to university technologies.

237
If there are other justifications for these patents, then Bayh–Dole theory
and practice must be modified to encompass these. And whatever the best publicspirited justification for Bayh–Dole patents is, policymakers should consider
whether alternative legal rules—such as requiring a market test—would better
align university incentives with the public interest.

